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Abstract
Essential genes (EGs) play central roles in fundamental cellular processes and are required for the
survival of an organism. EGs are enriched for human disease genes and are under strong purifying
selection. This intolerance to deleterious mutations, commonly observed haploinsufficiency and the
importance of EGs in pre- and postnatal development suggests a possible cumulative effect of
deleterious variants in EGs on complex neurodevelopmental disorders. Autism spectrum disorder (ASD)
is a heterogeneous, highly heritable neurodevelopmental syndrome characterized by impaired social
interaction, communication and repetitive behavior. More and more genetic evidence points to a polygenic
model of ASD and it is estimated that hundreds of genes contribute to ASD. The central question
addressed in this dissertation is whether genes with a strong effect on survival and fitness (i.e. EGs) play
a specific role in ASD risk. I compiled a comprehensive catalog of 3,915 mammalian EGs by combining
human orthologs of lethal genes in knockout mice and genes responsible for cell-based essentiality. With
an updated set of EGs, I characterized the genetic and functional properties of EGs and demonstrated the
association between EGs and human diseases. Next I provided evidence for a stronger contribution of
EGs to ASD risk, compared to non-essential genes (NEGs). By examining the exonic de novo and inherited
variants from 1,781 ASD quartet families, I demonstrated a significantly higher burden of damaging
mutations in EGs in ASD probands compared to their non-ASD siblings. Analysis of EGs in the developing
brain identified clusters of co-expressed EGs implicated in ASD, among which I proposed a priority list of
29 EGs with potential ASD risk as targets for future functional and behavioral studies. Finally, I developed
the essentiality burden score (EBS), which captures the burden of rare mutations in EGs as a novel
polygenic predictor of individual ASD risk and a useful addition to the current tools for understanding the
polygenic architecture of ASD. Overall, I show that large-scale studies of gene function in model
organisms and human cell lines provide a powerful approach for prioritization of genes and pathogenic
variants identified by sequencing studies of complex human disease.
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ABSTRACT
ESSENTIAL GENES AND THEIR ROLE IN AUTISM SPECTRUM DISORDER
Xiao Ji
Maja Bucan
Essential genes (EGs) play central roles in fundamental cellular processes and are
required for the survival of an organism. EGs are enriched for human disease genes and
are under strong purifying selection. This intolerance to deleterious mutations, commonly
observed haploinsufficiency and the importance of EGs in pre- and postnatal
development suggests a possible cumulative effect of deleterious variants in EGs on
complex neurodevelopmental disorders. Autism spectrum disorder (ASD) is a
heterogeneous, highly heritable neurodevelopmental syndrome characterized by impaired
social interaction, communication and repetitive behavior. More and more genetic
evidence points to a polygenic model of ASD and it is estimated that hundreds of genes
contribute to ASD. The central question addressed in this dissertation is whether genes
with a strong effect on survival and fitness (i.e. EGs) play a specific role in ASD risk. I
compiled a comprehensive catalog of 3,915 mammalian EGs by combining human
orthologs of lethal genes in knockout mice and genes responsible for cell-based
essentiality. With an updated set of EGs, I characterized the genetic and functional
properties of EGs and demonstrated the association between EGs and human diseases.
Next I provided evidence for a stronger contribution of EGs to ASD risk, compared to
non-essential genes (NEGs). By examining the exonic de novo and inherited variants
from 1,781 ASD quartet families, I demonstrated a significantly higher burden of
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damaging mutations in EGs in ASD probands compared to their non-ASD siblings.
Analysis of EGs in the developing brain identified clusters of co-expressed EGs
implicated in ASD, among which I proposed a priority list of 29 EGs with potential ASD
risk as targets for future functional and behavioral studies. Finally, I developed the
essentiality burden score (EBS), which captures the burden of rare mutations in EGs as a
novel polygenic predictor of individual ASD risk and a useful addition to the current
tools for understanding the polygenic architecture of ASD. Overall, I show that largescale studies of gene function in model organisms and human cell lines provide a
powerful approach for prioritization of genes and pathogenic variants identified by
sequencing studies of complex human disease.
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CHAPTER 1: Introduction
One of the central goals of human genetics studies is to understand the genetic
contribution to human diseases. This knowledge is of great value in combating disease
and promoting human health. The genes responsible for a wide range of Mendelian
disorders, such as sickle cell anemia, cystic fibrosis, and Huntington’s disease, have been
well understood by the genetics community (Stenson et al., 2014). However, it has been a
challenge to identify risk genes and variants underlying a majority of common complex
diseases including cardiovascular diseases, cancer, diabetes and psychiatric disorders,
where complicated interactions of multiple genes and environmental factors are involved
in their etiology (Risch, 2000; Wray et al., 2014). There has been an ongoing debate in
the field of genetics over how genetic variations contribute to the risk of common
complex diseases. The ‘common disease-common variant’ hypothesis predicts that
common genetic variants with low penetrance are the major contributors of individual
susceptibility to complex diseases. In contrast, the ‘common disease-rare variant’
hypothesis argues that the risk of complex disease is mainly due to rare variants that are
more specific to individuals with relatively high penetrance. Both hypotheses have their
place in current research and are supported by substantial evidence, therefore it is
important to evaluate the contribution of both common and rare variants to the risk of
complex diseases (Gibson, 2012; Schork et al., 2009). The key to identifying genetic
variants contributing to complex diseases is to pinpoint risk genes and variants from a
huge number of those that are biologically insignificant or irrelevant for that disease.
1

Important advances in the study of complex disease were the development of
technologies that enable systematic interrogation of many genetic variants in large
cohorts of patients. Single nucleotide polymorphism (SNP) array-based genome-wide
association studies (GWAS) represent a powerful tool for uncovering the common
genetic variants that underlie risk of complex diseases. Furthermore, next generation
sequencing technologies enable the investigation of the role of low-frequency or rare
variants in complex diseases, which may explain additional disease risk or trait
variability. However, despite the genetic associations discovered though the studies of
both common and rare variants, a full understanding of the genetic architecture of most
complex disorders has yet to be achieved.
One of the substantial challenges for current sequencing-based association studies of
complex diseases comes from the limitation of the classical single variant-based
association test, where limited sample sizes, modest effect sizes of variants and the
multiple testing burden restricts its statistical power (Lee et al., 2014). As an alternative
approach, aggregation tests that evaluate the cumulative effect of multiple variants in a
gene or region can increase statistical power when a group of variants are associated with
a disease or trait of interest (Lee et al., 2014; Li and Leal, 2008; Madsen and Browning,
2009; Wu et al., 2011). Following the concept of gene- or region-level aggregation tests,
a top-down strategy starts from identifying a large set of genes with key characteristics
that are known to play a role in studied diseases. Groups of variants in these candidate
gene sets are then jointly tested in order to increase statistical power. This strategy was
applied by a number of recent genetic studies of schizophrenia. For example, Purcell et
2

al. performed a polygenic burden test of rare disruptive mutations in schizophrenia
candidate gene sets (including synaptic genes, voltage-gated calcium channel genes and
targets of the fragile X mental retardation protein) using exome sequences of ~2,500
schizophrenia cases and ~2,500 controls (Purcell et al., 2014). In addition, copy number
variant (CNV) burden within gene sets involved in neurodevelopmental or neurological
function was assessed in a schizophrenia cohort of ~20,000 cases and ~20,000 controls
(Cnv et al., 2017). These studies provided a proof-of-principle that the candidate gene set
approach which evaluates the aggregational effect of multiple variants can facilitate the
discovery of risk alleles in neuropsychiatric diseases.
Of all of the genes in the genome, there is a subset of essential genes (EGs) that play
central functional roles and are required for the survival of an organism. The
identification and characterization of the core set of genes that are necessary for basic
developmental functions, i.e. the “essentialome”, is an important biological question by
itself, as it provides insights into the molecular basis for key biological processes in
multiple organisms including human (Zhan and Boutros, 2016). In S. cerevisiae (budding
yeast), ~ 20% of ~ 6,000 genes are necessary for viability and proliferation in rich
medium (Giaever et al., 2002; Winzeler et al., 1999). However, in addition to the core set
of EGs that result in lethal phenotype upon loss, there are other genes that are
conditionally essential. These genes have been extensively studied in S. cerevisiae. It has
been shown that yeast mutants with one of these genes deleted are sensitive to additional
perturbations such as stress conditions (Giaever et al., 2002), chemicals (Costanzo et al.,
2010; Hillenmeyer et al., 2008) and knock out of a second gene (i.e. synthetic lethality)
3

(Costanzo et al., 2010; Nijman, 2011). Therefore, deciding whether these genes also
count as essential is a matter for discussion. In multicellular organisms, many EGs are
housekeeping genes that are required for maintaining basal cellular functions and tend to
be ubiquitously expressed at constant levels in all cell types (Eisenberg and Levanon,
2013). However, some other EGs in multicellular organisms can be restricted to the
function of specific tissues or certain developmental stages (Zhan and Boutros, 2016).
For example, mice with targeted disruption of Fatp4 gene that encodes a fatty acid
transport protein died shortly after birth because of a skin defect (Herrmann et al., 2003).
The Fatp4 knockout mice could be rescued by introducing transgenic expression of
Fatp4 in skin cells (Shim et al., 2009). In contrast, adipocyte-specific inactivation of
Fatp4 did not result in severe phenotypes in mice (Lenz et al., 2011), showing that Fatp4
is likely to be required for the proper function of a single tissue, whereas it is essential for
the viability of the whole organism. In the scope of this dissertation, I defined an EG as a
gene that causes lethality of a multicellular organism when fully knocked-out, whether
the gene is essential in all tissues or not.
Historically, forward genetics strategies based on chemically induced, radiation-induced
or insertional mutagenesis had been extensively applied to investigate the link between
genotypes and phenotypes (Zhan and Boutros, 2016). In C. elegans, Clark et al. and
Johnsen & Baillie independently identified hundreds of lethal mutations in specific
chromosomal regions using ethyl methanesulfonate (EMS) mutagenesis. They estimated
that the total number of EGs in C. elegans is at least 2,850~3,500, which accounts for
15~18% of all protein coding genes in the C. elegans genome (Clark et al., 1988; Johnsen
4

and Baillie, 1991). In D. melanogaster, P-transposable element has been widely used to
disrupt Drosophila genes. For instance, the Berkeley Drosophila Genome Project
generated mutant lines for 40% of Drosophila genes and observed that 8~16% of genes
led to lethal phenotypes when disrupted (Bellen et al., 2004).
Built on the foundation of the completed genome sequences of many model organisms,
reverse genetics approaches enabled the exploration of gene essentiality on a genomewide scale. RNA interference (RNAi) based gene silencing has been proved to be a
successful strategy in discovering EGs. Kamath et al. used RNAi to inhibit the function
of ~16,700 genes in C. elegans, and identified mutant phenotypes of 1,722 genes. 68% of
these genes (n=1,170) exhibited nonviable RNAi phenotypes (Kamath et al., 2003).
Boutros et al. performed genome-wide RNAi analysis of the growth and viability in
Drosophila cells and identified 438 EGs, among which 80% lacked known mutant alleles
in Drosophila (Boutros et al., 2004). Dietzl et al. generated a genome-wide library of
22,270 RNAi transgenic Drosophila lines that covered 88% of the predicted proteincoding genes in Drosophila, among which 17.5% of transgenic lines exhibited lethal
phenotypes (Dietzl et al., 2007). While these studies generated sizable catalogs of EGs in
studied organisms, the percentages of EGs discovered varied in these studies due to
common limitations of RNAi screens such as variability and incompleteness of
knockdowns as well as potential nonspecificity of RNAi targets (Boutros and Ahringer,
2008). Regardless, these studies do not necessarily contradict the estimation from Miklos
& Rubin that around one third of genes are essential for viability in these model
organisms (Miklos and Rubin, 1996).
5

Identification of EGs in the mouse is of particular interest due to the evolutionary
closeness between mouse and human, as well as the great potential of mouse models in
translational research. Over decades, the genetics community collected a substantial
amount of phenotypic data in knockout mouse strains generated by both forward and
reserve genetics approaches such as ethyl-nitrosourea (ENU) mutagenesis, transposon
mutagenesis, gene trapping and gene targeting in mouse embryonic stem cells (Eppig et
al., 2005). Based on reported homozygous embryonic/perinatal lethal mouse mutants, it
was estimated that ~30% of mouse genes are essential for mouse viability (Dickinson et
al., 2016; White et al., 2013). Due to the extensive similarity between the genomes of
mouse and human, human EGs can be inferred from the human orthologs of prenatal or
preweaning lethal genes in the mouse (Dickerson et al., 2011; Feldman et al., 2008;
Georgi et al., 2013; Goh et al., 2007; Park et al., 2008). We are particularly interested in
the potential connection between EGs and human disease. Earlier studies of human
orthologs of EGs in the mouse proposed that the majority of human disease genes are
non-essential, because mutations in EGs prevent viability and thus do not contribute to
human disease (Domazet-Loso and Tautz, 2008; Feldman et al., 2008; Goh et al., 2007;
Park et al., 2008) . However, the role of EGs in human disease could be underestimated,
since some of these studies also presented contrasting evidence showing that human
disease genes can also display some characteristics of EGs, such as high connectivity in
gene networks (Goh et al., 2007) and an early evolutionary emergence (Domazet-Loso
and Tautz, 2008). More recent studies on human orthologs of EGs in the mouse began to
redefine the role of EGs in human disease. With an analysis of the overlap between 1,299
EGs and known human disease genes, Dickerson et al. pointed out that EGs actually
6

comprised a major portion of disease genes (Dickerson et al., 2011). Georgi et al.
reinforced this notion by showing an enrichment of disease genes among an updated list
of 2,472 human orthologs of EGs in the mouse (Georgi et al., 2013).
To better understand to role of EGs in human disease, it is helpful to clarify the
difference in mutational spectrums of EGs and non-essential genes (NEGs). In a diseaseassociated NEG, we may observe disease phenotypes when homozygous loss-of-function
mutations or compound heterozygosity of null alleles occur in an individual. However in
an EG, we won’t observe homozygous loss-of-function mutations in living individuals
because they cause lethality. Instead, EGs could contribute to human disease through
milder alleles other than functionally null alleles (Figure 1.1). It has been shown that EGs
exhibit a reduced number of exonic missense (Georgi et al., 2013; Petrovski et al., 2013)
and loss-of-function (Lek et al., 2016) variants in general population, as well as a shift in
allele frequency towards rare alleles (Georgi et al., 2013). Moreover, previous studies
showed evidence that EGs are prone to exhibiting haploinsufficiency (Deutschbauer et
al., 2005; Georgi et al., 2013), which suggests that heterozygous alleles in EGs are more
likely to be deleterious and pathogenic. These observations support the functional
importance of EGs in humans and implicate that EGs are more likely to have functional
consequences when mutated.
In this dissertation, I investigated the connection between EGs and human diseases, with
a focus on a neurodevelopmental disease - autism spectrum disorder (ASD). ASD is a
neurodevelopmental disorder characterized by repetitive behavior and impairments in
social interaction, communication and language (2013). The signs of autism begin to
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appear over the first year of life (Ozonoff et al., 2008). According to the latest survey
from the Centers for Disease Control and Prevention, the prevalence of ASD is 1 in 68,
and males are 4.5 times more likely to develop ASD compared to females (Christensen,
2016). There is general agreement across family and twin studies that the heritability of
ASD is between ~60% to ~90% (Bailey et al., 1995; Folstein and Rutter, 1977;
Hallmayer et al., 2011; Lichtenstein et al., 2010; Ronald and Hoekstra, 2011; Sandin et
al., 2014). The genetic causes of ASD are highly heterogeneous among patients, and
identified ASD linked mutations accounting for more than 1% of ASD cases are very rare
(Jeste and Geschwind, 2014; State and Sestan, 2012). It has been demonstrated that
common variants carry a substantial ASD risk (Anney et al., 2012; Gauglerl et al., 2014;
Klei et al., 2012; Wang et al., 2009), which supports the ‘common disease-common
variant’ hypothesis in ASD. Based on this hypothesis, a number of ASD risk loci were
discovered through genetic linkage analysis (Szatmari et al., 2007; Weiss et al., 2009)
and GWAS (Anney et al., 2010; Ma et al., 2009; Wang et al., 2009). However, it is
difficult to identify and replicate the ASD-linked common variants by these traditional
genetic tests due to their small effect sizes and currently limited sample size (~5,000
ASD cases). Based on the “common disease-rare variant” hypothesis, many ASD studies
that focused on protein-disrupting, rare de novo variants in affected children have
successfully implicated hundreds of single nucleotide variants (SNVs) and copy number
variants (CNVs) as potential ASD risk factors (Bucan et al., 2009; De Rubeis et al., 2014;
Gilman et al., 2011; Glessner et al., 2009; Gratten et al., 2013; Griswold et al., 2012;
Iossifov et al., 2014; Iossifov et al., 2012; Itsara et al., 2010; Levy et al., 2011; Marshall
et al., 2008; Neale et al., 2012; O'Roak et al., 2012a; O'Roak et al., 2012b; Pinto et al.,
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2010a; Sanders et al., 2011; Sanders et al., 2012; Sebat et al., 2007; Szatmari et al.,
2007). However, a large proportion of ASD heritability remains unexplained and the
genetic mechanisms involved in ASD are still not fully understood. As a way to explain
the complexity of the genetic architecture of ASD, more and more genetic evidence
points to a polygenic model of ASD (de la Torre-Ubieta et al., 2016), i.e. at least
hundreds of genes and a large number of common variants with modest effect, and rare or
de novo variants with strong effect, contributing to ASD risk collaboratively.
The early on-set of ASD suggests a prenatal or early postnatal origin. Multiple lines of
evidence implicated that impairments of early brain development were involved in the
pathogenesis of ASD (Parikshak et al., 2013; Stoner et al., 2014; Willsey et al., 2013a).
For instance, Parikshak et al. found that ASD genes from multiple sources converged on
pathways implicated in prenatal and early post natal synaptic development (Parikshak et
al., 2013). Willsey et al. reported convergence of ASD genes on midfetal deep cortical
projection neurons (Willsey et al., 2013a). Stoner et al. observed disorganization of
neurons in prefrontal and temporal cortical tissues in 10 of 11 autistic children and
suggested that such abnormality emerged at prenatal developmental stages (Stoner et al.,
2014). Therefore, EGs as a group of genes that are required for normal pre- and postnatal
development are prime candidates for the analysis of the polygenic architectures of ASD.
The objective of this dissertation is to systematically investigate the potential link
between EGs and ASD, which was proposed by Georgi et al., who observed that genes
with de novo events in ASD patients are enriched for EGs (Georgi et al., 2013).
Furthermore, the two hit model of neuropsychiatric disorders was initially proposed by
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Girirajan & Eichler to explain the phenotypic variability among patients. This model
suggests that in a network of genes in a pathway associated with neuropsychiatric
disorders, a single hit initially disrupts the pathway and results in a milder phenotype, and
a second hit further damages the pathway to generate a much more severe phenotype
(Girirajan and Eichler, 2010). Therefore, in neurodevelopmental disorders where
individual candidate genes cannot fully explain their genetic basis, it is possible that
multiple deleterious variants in EGs constitute a genetic background that influences an
individual’s disease risk. I hypothesized that a cumulative effect of a range of alleles in
EGs may contribute to developmental or behavior anomalies such as ASD. In this thesis,
my aims are to address these challenges as follows.
In Chapter 2, I identified and compiled the most comprehensive set of EGs to-date by
combining data from cell-based assays in human cell lines and systematically phenotyped
knock-out mice. I characterized the genetic and functional properties of EGs and
demonstrated the association between EGs and human disease.
In Chapter 3, I provided compelling evidence for a significant contribution of EGs to
ASD risk compared to NEGs by showing a higher burden of damaging mutations in EGs
in ASD probands and enrichment of EGs among currently known ASD risk genes.
Moreover, I identified clusters of co-expressed EGs implicated in ASD through the
analysis of EGs in the developing brain.
In Chapter 4, I developed the essentiality burden score (EBS), based on exonic rare
variants in EGs, as a novel predictor to ASD risk. I compared EBS, polygenic risk score
10

(PRS), and rare CNV burden to evaluate their performance in predicting ASD disease
risk. Furthermore, I investigated the interplay between EBS and rare variants in a highpenetrant ASD risk gene, NRXN1.
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Figures

Figure 1.1 Distinct mutational spectrums of variants in essential and non-essential
genes. Loss-of-function variants (in red) in both alleles (circles) of essential genes (A)
lead to lethality or miscarriages when homozygous (depicted as embryo) and are likely to
lead to a disease phenotype (shaded gray) when they are heterozygous. Loss-of-function
variants in many non-essential genes (B) produce a disease phenotype when homozygous
and no disease phenotype when heterozygous (shaded white). Hypomorph alleles
(yellow) in essential genes may produce a disease phenotype when homozygous or may
lead to lethality when combined with another hypomorph or loss-of-function allele in the
same gene. Benign alleles are depicted with different colored circles.
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CHAPTER 2: Characterization of essential genes
Introduction
Research of gene essentiality has potential implications for the genetic basis of human
disease. However, it is difficult to identify EGs directly from human studies because null
mutations in EGs are missing in living individuals. A number of EGs were implicated
through case studies of families with mutations in genes linked to miscarriages or lethal
birth defects (Malfatti et al., 2014; Michalk et al., 2008; Stangenberg et al., 1992).
Because of low sample sizes available for these case studies, the number of human EGs
discovered through this method is limited. For example, Stangenberg et al. reported a
patient with recurrent miscarriages who delivered a hydropic stillborn infant with βGlucuronidase (GUSB) deficiency (Stangenberg et al., 1992). Michalk et al. found that
one fetus had homozygous loss-of-function mutations in CHRNA1 which could disable
the function of acetylcholine receptor and lead to intrauterine death (Michalk et al.,
2008). Moreover, Malfatti et al. reported five NEB-mutated infants who presented severe
congenital myopathy leading to death in the first day after birth (Malfatti et al., 2014).
Interestingly, the mouse orthologs of GUSB, NEB and CHRNA1 also cause pre- or
perinatal lethality when knocked out in mouse, according to phenotypic data of knockout
mice from Mouse Genome Informatics (MGI) (Eppig et al., 2005).
In order to systematically investigate gene essentiality in human, EGs are often inferred
from the human orthologs of prenatal or preweaning lethal genes in the mouse based on
the extensive similarity between the genomes of mouse and human (Dickerson et al.,
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2011; Feldman et al., 2008; Georgi et al., 2013; Goh et al., 2007; Park et al., 2008). For
example, using phenotypic data of knockout mice from MGI (Eppig et al., 2005),
Dickerson et al. and Georgi et al. identified 1,299 and 2,472 human orthologs of lethal
genes in the mouse, respectively (Dickerson et al., 2011; Georgi et al., 2013). Based on
targeted mutant embryonic stem cells generated by the International Knock-out Mouse
Consortium (IKMC) (Skarnes et al., 2011), the International Mouse Phenotyping
Consortium (IMPC) generated and phenotyped 1,751 new knockout mouse lines on a
uniform C57BL/6N background, among which 410 knockout lines displayed preweaning
lethality (Dickinson et al., 2016). This study is consistent with previous observation that
30% (or ∼6,000) of protein-coding genes are essential for pre- and postnatal survival in
the mouse (Dickinson et al., 2016; White et al., 2013). Remarkably, the IMPC also

identified 198 subviable knockout lines, which demonstrated that some genes may exhibit
incomplete penetrance and variable expressivity even on a defined genetic background
(Dickinson et al., 2016).
Human cell line based assays are complementary approaches to identify human EGs.
RNA interference (RNAi) libraries targeting the human genome enabled earlier studies to
identify cell EGs (Harborth et al., 2001; Luo et al., 2008; Silva et al., 2008). For example,
Luo et al. performed RNAi screens in 12 cancer cell lines and identified 268 common
EGs among the 12 cell lines (Luo et al., 2008). Recently, three genome-wide scale
screens based on CRISPR/Cas9 gene editing system have been performed to assess the
effect of single-gene disruption on survival of haploid human cancer cell lines (Blomen et
al., 2015; Hart et al., 2015; Wang et al., 2015). These studies systematically uncovered
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genes responsible for cell-based essentiality in human cell lines in a genome-wide scale.
Wang et al. presented 1,878 cell essential genes in the near-haploid chronic myeloid
leukemia cell line KBM7 (Wang et al., 2015). Blomen et al. identified 1,734 genes that
were required for optimal growth for both KBM7 and HAP1 cell lines (Blomen et al.,
2015). Hart et al. observed 1,580 genes whose perturbation decreased cell growth and
proliferation in more than three studied cell lines (Hart et al., 2015). Although the core
EGs discovered in these studies overlap greatly, the number of EGs identified in each
study varies because different cell lines were selected and different thresholds were used
for determining cell viability.
Previous studies have reported some key characteristics of EGs. Firstly, EGs tend to
encode hub proteins that are most highly connected in biological networks (Goh et al.,
2007; Jeong et al., 2001), showing the functional importance of EGs. Secondly, EG are
often highly conserved across species. The conservation of EGs is supported by several
comparative genomic studies in bacterial genomes (Bergmiller et al., 2012; Gerdes et al.,
2003; Jordan et al., 2002; Luo et al., 2015) and Georgi et al., who found that EGs exhibit
increased conservation across rodent and primate lineages compared to the rest of genes
in the genome (Georgi et al., 2013). Thirdly, EGs are more likely to be under purifying
selection, which is supported by observations that EGs were intolerant to exonic missense
(Georgi et al., 2013; Petrovski et al., 2013) and loss-of-function (Lek et al., 2016)
variants in general populations. Lastly, EGs are prone to exhibiting haploinsufficiency, as
is suggested by both Deutschbauer et al. and Georgi et al. who found enrichment of EGs
among haploinsufficient genes (Deutschbauer et al., 2005; Georgi et al., 2013).
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In this chapter, I set out to compile a comprehensive list of EGs in human by combining
the legacy mouse phenotyping data from MGI (Eppig et al., 2005), the newly uncovered
lethal and subviable mouse genes from IMPC and human cell EGs from recent
CRISPR/Cas9-based studies. With an updated set of EGs, I characterized the genetic and
functional properties of EGs and confirmed the association between EGs and human
disease.
Results
Identification of a comprehensive list of human orthologs of essential genes in the
mouse
To identify a comprehensive list of human orthologs of EGs in the mouse, I established
orthology between genes in mice and humans (Eppig et al., 2005), and used the Human
Genome Mutation Database (HGMD) (Stenson et al., 2014) to annotate human disease
associations. I next combined the published data from the MGI database (MP terms listed
in Table 2.1) and 608 genes identified in the IMPC effort as causing lethality and
subviability to compile an updated list of 3,326 EGs, along with 4,919 nonessential genes
(NEGs).
The IMPC effort expanded a phenotypic spectrum for over 300 genes associated with
known Mendelian diseases. From 194 subviable genes with identified human orthologs,
57 were associated with human disease, of which 34 were previously unreported for their
subviable phenotypes (Supplementary Data 2.1; new reports indicated by ‘N’ in column
J). For example, SET binding protein 1 (SETBP1) has been reported as frequently
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mutated in several types of chronic leukaemia and in Schnizel-Giedion syndrome, a
congenital disease characterized by a high prevalence of tumors, severe mid-face
hypoplasia, heart defects and skeletal anomalies (Piazza et al., 2013; Schinzel and
Giedion, 1978). Among 399 lethal genes, 126 human orthologs have been associated with
human diseases, including 52 disease genes for which the IMPC effort provides the first
report of their null phenotype in the mouse (Supplementary Data 2.2). The human
orthologs of these novel lethal genes have been linked to metabolic and storage
syndromes (ADSL, DHFR, GYG1, PC), mitochondrial complex deficiencies (ATP5E,
NDUFS1, NUBPL, SDHA, SLC25A3, UQCRB), or syndromes caused by disruption of
basic processes such as replication or translation initiation (EIF2B3, EIF2B4, ORC1).
The severity of clinical manifestation of these human syndromes ranges from neonatal
lethality (BBS10, SLC25A3) matching the observed phenotype in the mouse, to
neurological disorders and intellectual disability (COQ6, DEPDC5, GOSR2, KDM5C,
YARS). These differences in clinical manifestation may be due to differences between
underlying biological processes in the mouse and human.
Expansion of the essential gene list through genome-wide screens for cell-essential
genes in human cell lines
I used data from three recent publications on genome-wide screens for cell-essential
genes in human cells to address the overlap between essential genes in the human and
mouse genome (Blomen et al., 2015; Hart et al., 2015; Wang et al., 2015). I selected core
essential human genes from each study and compared these to the human orthologs of
mouse essential genes on the consensus list of curated IMPC-MGI genes (see Materials
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and Methods). I found that approximately 35% of core essential genes in each study were
associated with lethality or subviability in the mouse, and that mouse null-phenotypes for
61–62% of genes were currently unknown (Figure 2.1). Of the 19 human essential genes
common to all three studies that were nonessential in the mouse, only three (Rbmx, Dkc1,
and Sod1) could reliably be confirmed as a targeted knockout of a nonessential gene,
highlighting the remarkable concordance between mouse and human in their core
essential genes.
From these cell-based studies of EGs, I identified an overlapping core set of genes that
were essential in the majority of cell lines tested (n = 956), but not necessarily all cell
lines tested. To identify the most comprehensive set of EGs in mammals, I combined the
set of human orthologs of EGs in the mouse (n =3,326) with a set of human “core EGs”
(n = 956) that were found to be essential in cell-based assays (Blomen et al., 2015; Hart
et al., 2015; Wang et al., 2015). Based on the significant overlap between tested mouse
and human EGs, I expanded our original set of 3,326 EGs with the addition of
nonoverlapping 589 EGs identified only in human cell lines for a total of 3,915 EGs
(Materials and Methods, Supplementary data 2.3). In my subsequent analyses, I analyzed
and compared the features of these 3,915 EGs with 4,919 human orthologs of genes with
reported nonlethal phenotypes in the mouse [nonessential genes (NEGs)].
Enrichment of human disease genes and genes neighboring GWAS hits among
essential genes
It has been shown that genes causing lethality in mice are enriched in human disease
genes (Dickerson et al., 2011; Georgi et al., 2013). With these updated EG lists, I report
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an even stronger enrichment of essential genes relative to nonessential for human disease
genes catalogued in the HGMD (odds ratio = 2.00, P = 6.83 × 10−39, Figure 2.2A).
Consistent with this enrichment, of the 3,302 protein-coding HGMD disease genes, 2,434
have a reported phenotype and more than half (1,253) are essential in mice (Figure 2.2B;
Supplementary Data 2.3). Furthermore, I found an enrichment of EGs in comparison to
nonessential genes (odds ratio = 1.16, P value = 0.0015) among 6,384 genes
encompassing or neighboring the disease- and trait-associated variants in the NHGRIEBI catalogue of published genome-wide association studies (‘GWAS hits’) (Welter et
al., 2014) (Figure 2.3).
Essential genes’ intolerance to deleterious mutations
With the updated catalog of mouse 3,326 EGs and 4,919 NEGs, I compared the
mutability of their human orthologs in exome sequences of 60,706 subjects in the Exome
Aggregation Consortium data (ExAC, http://exac.broadinstitute.org) (Lek et al., 2016).
The ExAC data were used to generate intolerance scores for all protein-coding genes by
two complementary methods: a) the residual variation intolerance score (RVIS), which is
based on intolerance to common missense and truncating single nucleotide variation
(http://genic-intolerance.org/) (Petrovski et al., 2013); and b) the estimation of probability
of being loss-of-function intolerant (pLI score) (Lek et al., 2016). Human orthologs of
EGs are more intolerant to variation (low RVIS and high pLI scores) than orthologs of
NEGs and all genes in the human genome (P value < 2.2 × 10−16 for lower percentiles in
essential genes using the two scoring systems, Figure 2.4A, B). Moreover, the IMPC
effort identified a set of 22 human orthologs of EGs that were not previously associated
19

with human disease (Figure 2.5, Table 2.2), but based on their intolerance to functional
variation and lethality of their null alleles in the mouse, they represent strong candidates
for undiagnosed human diseases.
Chromosomal distribution of essential genes
EGs are distributed throughout the human genome, with the exception of the Y
chromosome (Figure 2.6). I identified 3 chromosomal regions, 17q21, 11q13 and 16q22,
with significant enrichment of EGs (FDR<0.05; one-sided Fisher’s exact test)
(Supplementary data 2.4). 17q21 contains 64 EGs which collectively cover 14.0% (1.69
Mb) of the total length of the region. 11q13 contains 63 EGs which collectively cover
15.5% (2.13 Mb) of the total length of the region. 16q22 contains 37 EGs which
collectively cover 29.3% (2.17 Mb) of the total length of the region. I further annotated
these three chromosomal regions with associated human diseases from OMIM (Hamosh
et al., 2005) and identified 91 human disease loci (including frontotemporal dementia,
progressive myoclonic epilepsy-6 and mental retardation) associated with 17q21, 59
disease loci associated with 11q13, as well as 30 disease loci associated with 16q22
(Supplementary data 2.4). Interestingly, 17q21 has been shown by replicated genomewide linkage studies (Cantor et al., 2005; Yonan et al., 2003) to harbor susceptibility to
autism spectrum disorder (ASD). In the mouse genome, I identified 2qB as the only
chromosomal region with significant enrichment of EGs in the mouse (44 EGs vs. 21
NEGs; P value =0.048; One-sided Fisher’s exact test after Bonferroni correction) (Figure
2.7, Supplementary data 2.5).
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Disease categories associated with essential genes
To systematically evaluate the relevance of EGs in diseases categorized by affected
tissues and age of onset, I obtained lists of human disease genes annotated by the Human
Phenotype Ontology (Kohler et al., 2017). First, I tested for enrichment of 3,915 EGs vs.
4,919 NEGs among 24 genes sets associated with abnormality of different organs or
systems. Except for one disease category (“Abnormality of the thoracic cavity”), all of
the gene sets associated with the rest of the 23 disease categories were significantly
enriched for EGs (Table 2.3), which suggests that disturbance of EGs may contribute to a
wide variety of diseases affecting different organs or systems. When genes were
categorized by the age of onset of their associated diseases, I observed that EGs are
significantly enriched among disease genes annotated as “congenital onset” (at birth)
(Odds ratio=3.84, P value=6.59×10-13; Two sided Fisher’s exact test), “neonatal onset”
(within 28 days) (Odds ratio=3.15, P value=0.015) and “infantile onset” (between 28
days and 1 year) (Odds ratio=2.44, P value=8.29×10-11), but not among genes annotated
as “childhood onset” (between 1 year and 5 years) (Odds ratio=1.01, P value=1),
“juvenile onset” (between 5 years and 15 years) (Odds ratio=1.16, P value=0.56) or
“adult onset” (16 years or later) (Odds ratio=1.43, P value=0.083) (Figure 2.8). These
results suggest that EGs may play a distinct role in early on-set diseases.
Expression patterns of essential genes across tissues
To evaluate the tissue specificity and ubiquitousness of EG expression, we analyzed the
expression patterns of EGs and NEGs over multiple human tissues using transcriptomic
data from GTEx (The GTEx Consortium, 2015). Compared to NEGs, a higher proportion
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of EGs are ubiquitously expressed and a lower proportion of EGs are specifically
expressed in certain tissues (Figure 2.9). Among 6,455 ubiquitously expressed genes
(entropy score>=5.5), there were 1,477 EGs and 941 NEGs, representing a significant
enrichment of EGs (Two-sided Fisher’s exact test: p-value=2.10×10-134, Odds ratio=3.42)
(Supplementary data 2.3). Among 1,680 genes specifically expressed in certain tissues
(entropy score<=1.0), there were 116 EGs and 415 NEGs, representing a significant
depletion of EGs (Two-sided Fisher’s exact test: p-value=1.58×10-29, Odds ratio=0.33).
The top 5 tissue types containing tissue-specifically expressed EGs were testis (with 27
EGs), liver (with 15 EGs), muscle (with 12 EGs), kidney (with 8 EGs) and brain (with 7
EGs) (Table 2.4).
Haploinsufficiency of essential genes
Homozygous loss-of-function mutations in EGs lead to lethality (or miscarriages in
humans) and as such, cannot contribute to disease. Although a depletion of loss-offunction mutations in EGs in humans was reported (Georgi et al., 2013; Petrovski et al.,
2013), heterozygosity for a loss-of-function mutation or other “milder” alleles in EGs
may contribute to both dominant and recessive diseases. I illustrate this point using a
catalog of disease-linked genes in Online Mendelian Inheritance in Man (Hamosh et al.,
2005). EGs were enriched relative to NEGs in 1,000 genes underlying dominant diseases
(odds ratio = 1.95, P value = 3.17 × 10−19; two-sided Fisher’s exact test) and 1,645 genes
underlying recessive disease (odds ratio = 1.52, P value = 4.94 × 10−11; two-sided
Fisher’s exact test) (Figure 2.10). A stronger enrichment of EGs among genes underlying
dominant disease compared to recessive disease implies that dominant negative alleles
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and haploinsufficiency play an important role. I provide multiple lines of evidence for
higher probability of haploinsufficiency of EGs (Figure 2.10). First, using the
systematically rated dosage-sensitive genes from ClinGen (Rehm et al., 2015), I found
that EGs were significantly enriched compared with NEGs and that the levels of EG
enrichment positively correlated with levels of evidence supporting dosage sensitivity of
rated genes (odds ratio = 3.94, P value = 5.07 × 10−20 for “sufficient evidence”; odds ratio
= 5.26, P value = 7.08 × 10−5 for “some evidence”; odds ratio = 2.52, P value = 0.0106
for “little evidence”; odds ratio = 1.14, P value = 0.608 for “not dosage sensitive”; twosided Fisher’s exact test). Second, as an extension of the earlier findings from the work
by Georgi et al. (Georgi et al., 2013), I confirmed the enrichment of EG relative to NEG
for 262 human haploinsufficient genes (Dang et al., 2008) with the updated EG and NEG
list (183 EGs vs. 62 NEGs; P value = 1.64 × 10−22, odds ratio = 3.84; two-sided Fisher’s
exact test). Third, EGs are significantly overrepresented among 313 human orthologs of
mouse genes with heterozygous alleles associated with mutant phenotypes from the MGI
(Eppig et al., 2005) (odds ratio = 3.43, P value = 2.74 ×10−23; two-sided Fisher’s exact
test). Fourth, with two genome-wide prediction models of haploinsufficient genes in the
human genome (Huang et al., 2010; Steinberg et al., 2015), I observed that EGs have
significantly higher probability of exhibiting haploinsufficiency compared with NEGs (P
value < 2.2 × 10−16 for both models; two-sided Wilcoxon rank sum test) (Figure 2.11 A
and B). Based on the findings that EGs linked to Mendelian disease are overwhelmingly
dosage-sensitive, in Chapter 3 I explored the possibility that a cumulative effect of
pathogenic variants in multiple EGs may underlie the genetic basis of a complex disease
with early postnatal onset, such as ASD.
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Discussion
I complied the most comprehensive EG set established to date (n=3,915) by combining
phenotypic data in knockout mice (n=3,326) and data from genomic-scale human cell
assays (n=956). I confirmed the important role of EGs in human disease by showing that
EGs comprise a major part of disease genes and that EGs are enriched among genes
neighboring GWAS hits. While EGs are distributed throughout the genome (with the
exception of the Y chromosome) and tend to be ubiquitously expressed across different
tissues, I identified three EG-enriched chromosomal regions, among which 17q21 was
associated with ASD according to replicated genome-wide linkage studies (Cantor et al.,
2005; Yonan et al., 2003). Finally, with an updated EG set, I confirmed that EGs are
intolerant to deleterious mutations and are more likely to be haploinsufficient.
The current catalog of human EGs includes 3,915 genes, which is a substantial increase
since the publication by Georgi et al. in 2013 (n=2,472) (Georgi et al., 2013). Based on
studies in the mouse, 30% of genes in a mammalian genome are essential (Dickinson et
al., 2016; White et al., 2013), meaning that the current catalog includes more than 65% of
the core set of “the indispensable genome”. With a major portion of EGs identified, the
general functional and genetic properties of EGs can be credibly characterized, as is
shown in this chapter. There is still a great amount work to be done to identify the
complete set of EGs. Systematically generating and phenotyping knockout mice for every
gene in the mouse genome (~20,000 genes) is a feasible strategy to achieve this goal,
which has been one of the main objectives of the International Mouse Phenotyping
Consortium (IMPC) (Dickinson et al., 2016; Koscielny et al., 2014).
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Recent breakthroughs in human cell line based assays on cell proliferation and survival
provided an effective alternative way to identify EGs in human (Blomen et al., 2015; Hart
et al., 2015; Wang et al., 2015). It overcomes some limitations of the knockout mice
based approach such as biological and genomic differences between mouse and human.
Indeed, some genes that are essential in one organism may not be essential in other
organisms, as is suggested by a few comparative genomic studies in bacterial genomes
(Bergmiller et al., 2012; Gerdes et al., 2003). However, the cell line based approaches
have their own drawbacks. Firstly, the precise number of cell EGs is difficult to
determine, since it depends on the chosen threshold for impaired fitness of cell lines
(Wang et al., 2015). Secondly, most of the genomic screens have been performed on
human cancer cell lines with gene knockouts. Cases of discrepancy may occur when
inferring organismal lethality from cancer cell survival rate. For example, the cancer cell
line based assays can reveal oncogenes (Luo et al., 2008) which may not necessarily be
essential in non-cancer cell lines. Therefore, careful examination and comparison of EGs
inferred from lethality of knockout mice and viability of human cell lines is warranted as
the catalog of known EGs grows continuously.
In contrast to earlier studies which suggested that human disease genes tend to be nonessential (Domazet-Loso and Tautz, 2008; Feldman et al., 2008; Goh et al., 2007; Park et
al., 2008), my results are consistent with the conclusions from Dickerson et al.
(Dickerson et al., 2011) and Georgi et al. (Georgi et al., 2013) that a major portion of
human disease genes are essential. The enrichment of EGs among human disease genes
from HGMD (Stenson et al., 2014) and genes neighboring GWAS hits (Welter et al.,
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2014) suggests that mutations in EGs contribute not only to Mendelian diseases, but also
to complex traits and disorders. My results on the enrichment of EGs among different
types of disease genes showed that while the contribution of EGs is widespread across
disorders with various affected systems and underlying mechanisms, EGs seems to play
an especially important role in early onset diseases. Homozygous loss-of-function
mutations in EGs are not present in living individuals. While EGs are generally intolerant
to other deleterious alleles at the population level, because of the functional importance
of EGs, observed deleterious alleles in EGs are more likely to be pathogenic. I confirmed
that EGs tend to demonstrate haploinsufficiency and an autosomal dominant model of
inheritance (Dickerson et al., 2011; Georgi et al., 2013), which supports a potential
cumulative effect of deleterious mutations (mostly in heterozygous state) in EGs on the
risk of early onset complex disorders, such as ASD.
Materials and Methods
Identification of essential genes and non-essential genes
I identified 3,023 protein-coding EGs annotated with 50 mouse phenotype (MP) terms,
including prenatal, perinatal, and postnatal lethal phenotypes from the MGI (Eppig et al.,
2005) (Table S8). The MGI database was also used to extract 4,995 protein-coding NEGs
with nonlethal phenotypes in the mouse. Phenotype data from the IMPC database portal
(Koscielny et al., 2014) expanded the lethal gene list with the addition of 252 lethal genes
and 101 genes with subviable phenotypes. I further supplemented the nonlethal gene list
with 701 genes with viable phenotypes from the IMPC. In the case of discrepancy in the
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reported lethality status between the MGI and the IMPC, I deferred to the phenotypes
reported by the IMPC, because these mouse lines were generated on a defined C57BL/6N
background and phenotypically characterized using a standardized pipeline.
One to one mouse–human orthology of lethal and nonlethal genes was established based
on MGI annotation and manual curation, resulting in 3,326 essential and 4,919
nonessential human orthologs (NEGs). The catalog of EGs was further augmented with
the addition of cell EGs from three recent studies (Blomen et al., 2015; Hart et al., 2015;
Wang et al., 2015) aimed at the characterization of EGs in human cell lines. I obtained
1,580 core EGs (genes above essentiality threshold in at least three of five cell lines in the
study) from the work by Hart et al. (Hart et al., 2015), 1,739 core EGs (genes above
essentiality threshold in at least two of four cell lines in the study) from the work by
Wang et al. (Wang et al., 2015), and 1,734 core EGs (genes above essentiality threshold
in at least one of two cell lines in the study) from the work by Blomen et al. (Blomen et
al., 2015). By taking the overlap of three sets of core EGs, I obtained 956 highconfidence human EGs. Among 956 EGs in human cell lines, 348 genes (36.4%) are also
human orthologs of EGs in the mouse, 19 genes (2.0%) are human orthologs of NEGs in
the mouse, and 589 genes (61.6%) have not been tested in the mouse.
Identification of genes encompassing or surrounding disease- and trait-associated
SNPs (‘GWAS hits’)
6,384 protein-coding genes encompassing and/or neighboring disease- or trait-associated
variants (‘GWAS genes’) were obtained from the GWAS Catalog (Welter et al., 2014)
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(downloaded on April 29, 2016). Specifically, I used the ‘mapped genes’ from the
GWAS Catalog, which are defined as the genes mapped to the strongest SNP from
GWAS reports. The mapped genes are defined as the genes encompassing the GWAS
SNP(s), (that is, located in coding or intragenic regions; n = 4,228) or the two genes that
map upstream and downstream of the GWAS SNP(s) (that is, in intergenic regions; n =
3,422). Enrichment of GWAS genes between our gene sets of interest was assessed by
two-sided Fisher’s exact test.
Categorization of human disease genes by the Human Phenotype Ontology
I categorized human disease genes collected by the Human Phenotype Ontology Project
(accessed the February 2017 release) (Kohler et al., 2017) based the subclasses of two
ontology terms: “Phenotypic abnormality” (HP:0000118) and “Onset” (HP:0003674). As
a result, I obtained 24 sets of disease genes annotated with abnormality in different
organs or systems (i.e. “Abnormality of prenatal development or birth”,“ Abnormality of
the breast”,“ Abnormality of the musculature”,“ Abnormality of limbs”,“ Abnormality of
the voice”,“ Growth abnormality”,“ Abnormality of the respiratory system”,“
Abnormality of the skeletal system”,“ Abnormality of head or neck”,“ Abnormality of the
digestive system”,“ Abnormality of the cardiovascular system”,“ Abnormality of the
eye”,“ Abnormality of connective tissue”,“ Abnormality of the genitourinary system”,“
Neoplasm”,“ Abnormality of the nervous system”,“ Abnormality of the ear”,“
Abnormality of the integument”,“ Abnormality of the immune system”,“ Abnormality of
blood and blood-forming tissues”,“ Abnormality of the endocrine system”,“ Abnormality
of metabolism/homeostasis”,“ Constitutional symptom” and“ Abnormality of the thoracic
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cavity”) , and 6 sets of genes annotated with different age of onset for their associated
diseases (i.e. “congenital onset”, “neonatal onset”, “infantile onset”, “childhood onset”,
“juvenile onset” and “adult onset”). For each set of disease genes, I evaluated the
enrichment of 3,915 EGs vs. 4,919 NEGs using two sided Fisher’s exact test. For a 2 * 2
contingency table with 4 cell counts: a (# EGs in target gene set), b (# EGs not in target
gene set), c (# NEGs in target gene set) and d (# NEGs not in target gene set), the 95%
confidence interval of odds ratio (OR) is calculated as follows:

1 1 1 1
𝑒𝑒𝑒[𝑙𝑛(𝑂𝑂) ± 1.96 ∗ � + + + ]
𝑎 𝑏 𝑐 𝑑
Chromosomal distribution of essential genes
The chromosomal distribution of 3,882 EGs with available coordinates in genome build
hg19 was plotted using Phenogram
(http://visualization.ritchielab.psu.edu/phenograms/plot). The enrichment of EGs across
cytobands was assessed by Enrichr (Chen et al., 2013).
Tissue specificity and ubiquitousness of gene expression
For each expression dataset, we measure the Shannon entropy score as suggested by
Schug et al.(Schug et al., 2005). The definition of tissue specificity score is shown below:
Suppose the expression levels of relevant genes were measured in N tissues in an
expression dataset, the relative expression level of gene g in tissue t was defined as:
pt|g = wg,t / ∑1 ≤ t ≤ N wg,t
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where wg,t is the measured expression level of gene g in tissue t.
The Shannon entropy (H) measuring the distribution of expression levels of gene g across
all tissues in an expression dataset was defined as:
Hg= ∑1 ≤ t ≤ N - pt|g log2(pt|g)
The tissue specificity score of gene g in tissue t is calculated as:
Qg|t = Hg - log2(pt|g)
Analysis of haploinsufficiency of essential genes
I collected genes sets from multiple studies and resources for the analysis of patterns of
inheritance and haploinsufficiency of EGs. First, a catalog of human disease genes was
obtained from Online Mendelian Inheritance in Man (OMIM; downloaded on July 12,
2016) (Hamosh et al., 2005). From the OMIM catalog, I identified 1,411 genes annotated
with genetic disorders that are “autosomal dominant” or “X-linked dominant” and 2,056
genes annotated with genetic disorders that are “autosomal recessive” or “X-linked
recessive.” By dissecting the above two gene lists, I obtained 1,000 genes underlying
only dominant diseases, 1,645 genes underlying only recessive diseases, and 441 genes
that were linked to both dominant and recessive disorders. Second, a list of 616 proteincoding genes that were systematically assessed for evidence for dosage sensitivity was
obtained from ClinGen Dosage Sensitivity Map (Rehm et al., 2015). Among 616 genes,
239 genes were dosage-sensitive with sufficient evidence, 41 genes were dosagesensitive with some evidence, 47 genes were dosage-sensitive with little evidence, 200
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genes had no evidence for dosage pathogenicity so far, and 89 genes were not dosagesensitive or with autosomal recessive phenotype. Third, a list of 262 haploinsufficient
genes based on textmining from PubMed and OMIM was obtained from the work by
Dang et al. (Dang et al., 2008). Fourth, from the MGI, I identified 313 human orthologs
of mouse genes associated with heterozygous phenotypes. For each of the gene sets, I
evaluated the enrichment of EGs compared with NEGs using Fisher’s exact test.
I acquired the Haploinsufficiency Scores (Huang et al., 2010) and the Genome-Wide
Haploinsufficiency Scores (Steinberg et al., 2015) for genome-wide prediction of the
probability of haploinsufficiency. For each prediction model, the raw scores were ranked
and converted to percentiles. The histograms and estimated density curves were plotted
using ggplot2 (geom_histogram and geom_line) in R.
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Figures

Figure 2.1 Overlap between essential genes in human cells and human orthologs of
essential genes in the mouse. Core essential genes in human cells identified in three
studies: 1,580 (Hart et al., 2015), 1,739 (Wang et al., 2015), and 1,734 (Blomen et al.,
2015) (top row) (see Methods). Pie charts indicate overlap between core human cellessential genes and orthologous genes in the mouse: essential (EG, red); nonessential
(NEG, green) and genes with unknown function in the mouse (Unknown, blue).
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Figure 2.2 Enrichment of essential genes among HGMD human disease genes. (A)
The fractions indicate the number of HGMD disease genes (disease-causing mutations
(DM)) (n = 3,302) among 3,326 essential genes (EG, red); 4,919 nonessential genes
(NEG, green) and 19,568 protein-coding genes (All, blue). Fisher’s exact test for
enrichment: EG versus NEG (odds ratio = 2.00, P = 7.80 × 10−46), EG versus All (odds
ratio = 3.13, P = 2.42 × 10−160), NEG versus All (odds ratio = 1.56, P = 1.83 × 10−29). (B)
Essentiality status of 3,302 HGMD disease genes.
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Figure 2.3 Enrichment of essential genes among genes neighboring GWAS hits. The
fractions indicate the number of genes encompassing or neighboring GWAS hits (Welter
et al., 2014) (n = 6,384) divided by essentiality status (EG in red, NEG in green, All in
blue). Fisher’s exact test for enrichment: EG versus NEG (odds ratio = 1.16, P = 0.0015),
EG versus All (odds ratio = 1.56, P = 5.80 × 10−31), NEG versus All (odds ratio = 1.35, P
= 1.18 × 10−19).
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Figure 2.4 Essential genes are intolerant to deleterious mutations. (A) Distribution of
percentiles of the residual variation intolerance score (RVIS) across three classes of
genes: EG (in red), NEG (in green) and All (in blue). Wilcoxon rank-sum test: EG versus
NEG (P value < 2.2 × 10−16), EG versus All (P value < 2.2 × 10−16), NEG versus All (P
value = 0.579). (B) Distribution of percentiles of the probability of being loss of function
intolerant (pLI) across three classes of genes: EG (in red), NEG (in green) and All (in
blue). Wilcoxon rank-sum test: EG versus NEG (P value < 2.2 × 10−16), EG versus All (P
value < 2.2 × 10−16), All versus NEG (P value = 4.15 × 10−5).
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Figure 2.5 Chromosomal distribution of 22 human orthologs of mutation-intolerant
essential genes that are not currently included in the catalogs of Mendelian disease
genes. Red bars indicate the chromosomal positions of the exhibited genes.
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Figure 2.6 Chromosomal distribution of 3,915 human essential genes. Chromosomal
positions of EGs (hg19) are shown in red. Three chromosomal regions (17q21, 11q13 and
16q22) with significant enrichment of EGs are shown in blue.
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Figure 2.7 Chromosomal distribution of 3,879 essential genes in the mouse.
Chromosomal positions of EGs (mm10) are shown in red. The chromosomal region
(2qB) with significant enrichment of EGs is shown in blue.
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Figure 2.8 Essentiality statuses of human diseases genes categorized by age of onset.
The results (p values, odds ratios and 95% confidence intervals of odds ratios) of Fisher’s
exact tests of enrichment of 3,915 EGs vs. 4,919 NEGs for human disease genes
categorized by the age of onset of associated diseases were plotted.
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Figure 2.9 Tissue expression specificity of EGs and NEGs. The distribution of
Shannon entropy scores (Methods and Materials) for EGs (in red) and NEGs (in
turquoise) was shown as both histogram and estimated density curve. The numbers of
tissue-specific (entropy score<1.0) EGs are shown in the top bar plot.
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Figure 2.10 Haploinsufficiency of essential genes. For each class of genes with
different essentiality status (EG in red, NEG in turquoise, and unknown in gray), the
proportion of genes among each gene set of interest is plotted in Left. Dosage-sensitive
genes from ClinGen (Rehm et al., 2015) were classified into five categories (1, sufficient
evidence; 2, some evidence; 3, little evidence; 4, no evidence and 5, not
sensitive/recessive). Two-sided Fisher’s exact test was performed to assess the
enrichment of EGs vs. NEGs, and the P values were indicated. The odds ratios for
enrichment of EGs compared with NEGs and the 95% confidence intervals of odds ratios
are plotted in Right. OMIM, Online Mendelian Inheritance in Man (Hamosh et al., 2005).
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Figure 2.11 Distribution of genome-wide haploinsufficiency scores. Histograms and
estimated density curves indicating the distribution of (A) the Haploinsufficiency Score
(HIS) (Huang et al., 2010) and (B) the Genome-Wide Haploinsufficiency Score (GHIS)
(Steinberg et al., 2015) across three gene sets, including EGs (red), NEGs (turquoise),
and all protein-coding genes (56) (gray). EGs have significantly higher probability of
exhibiting haploinsufficiency compared with NEGs (P value < 2.2 × 10−16 for both
models; two-sided Wilcoxon rank sum test).
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Tables
Table 2.1 Mouse phenotype (MP) terms for lethal phenotypes.
MP ID

Lethality type

Lethality description

MP:0002058

neonatal lethality

death within the neonatal period after birth (Mus: P0)

MP:0002080

prenatal lethality

death anytime between fertilization and birth (Mus:
approximately E18.5)

MP:0002081

perinatal lethality

death anytime within the perinatal period (Mus: E18.5
through postnatal day 1)

MP:0002082

postnatal lethality

premature death anytime between the neonatal period and
weaning age (Mus: P1 to approximately 3 weeks of age)

MP:0006204

embryonic lethality before
implantation

death anytime between fertilization and implantation
(Mus: E0 to less than E4.5)

MP:0006205

embryonic lethality
between implantation and
somite formation

death anytime between the point of implantation and
somite formation (Mus: E4.5 to less than E8)

MP:0006206

embryonic lethality
between somite formation
and embryo turning

death anytime between somite formation and the
initiation of embryo turning (Mus: E8 to less than E9)

MP:0006207

embryonic lethality during
organogenesis

death anytime between embryo turning and the
completion of organogenesis (Mus: E9-9.5 to less than
E14)

MP:0006208

lethality throughout fetal
growth and development

MP:0008527

embryonic lethality at
implantation

MP:0008569

lethality at weaning

premature death at weaning age, often due to the inability
to make the transition to solid food

MP:0008762

embryonic lethality

death of an animal within the embryonic period prior to
organogenesis (Mus: prior to E14)

MP:0009850

embryonic lethality
between implantation and
placentation

death anytime between the point of implantation and the
initiation of placentation (Mus: E4.5 to less than E9)

MP:0010770

preweaning lethality

MP:0010831

partial lethality

death anytime between the completion of organogenesis
and birth (Mus: E14 to approximately E18.5)
death due to failure of implantation (Mus: E4.5)

death anytime between fertilization and weaning age
(Mus: approximately 3-4 weeks of age)
the appearance of lower than Mendelian ratios of
offspring of a given genotype due to death of some, but
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not all of the organisms
MP:0010832

lethality during fetal
growth through weaning

death anytime between the completion of organogenesis
and weaning age (Mus: E14 to approximately 3 weeks of
age)

MP:0011083

complete lethality at
weaning

premature death at weaning age of all organisms of a
given genotype in a population, often due to the inability
to make the transition to solid food

MP:0011084

partial lethality at weaning

the appearance of lower than Mendelian ratios of
organisms of a given genotype due to death of some, but
not all of the organisms at weaning age

MP:0011085

complete postnatal lethality

premature death anytime between the neonatal period and
weaning age of all organisms of a given genotype in a
population (Mus: P1 to approximately 3 weeks of age)

MP:0011086

partial postnatal lethality

the appearance of lower than Mendelian ratios of
organisms of a given genotype due to death of some, but
not all of the organisms anytime between the neonatal
period and weaning age (Mus: P1 to approximately 3
weeks of age)

MP:0011087

complete neonatal lethality

death of all organisms of a given genotype in a population
within the neonatal period after birth (Mus: P0)
the appearance of lower than Mendelian ratios of
organisms of a given genotype due to death of some, but
not all of the organisms within the neonatal period after
birth (Mus: P0)

MP:0011088

partial neonatal lethality

MP:0011089

complete perinatal lethality

death of all organisms of a given genotype in a population
within the perinatal period (Mus: E18.5 through postnatal
day 1)

MP:0011090

partial perinatal lethality

the appearance of lower than Mendelian ratios of
organisms of a given genotype due to death of some, but
not all of the organisms within the perinatal period (Mus:
E18.5 through postnatal day 1)

MP:0011091

complete prenatal lethality

death of all organisms of a given genotype in a population
between fertilization and birth (Mus: approximately
E18.5)

MP:0011092

complete embryonic
lethality

death of all organisms of a given genotype in a population
within the embryonic period prior to organogenesis (Mus:
prior to E14)

MP:0011093

complete embryonic
lethality at implantation

death of all organisms of a given genotype in a population
at the point of implantation (Mus: E4.5)

MP:0011094

complete embryonic
lethality before

death of all organisms of a given genotype in a population
between fertilization and implantation (Mus: E0 to less
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implantation

than E4.5)

MP:0011095

complete embryonic
lethality between
implantation and
placentation

death of all organisms of a given genotype in a population
between the point of implantation and the initiation of
placentation (Mus: E4.5 to less than E9)

MP:0011096

complete embryonic
lethality between
implantation and somite
formation

death of all organisms of a given genotype in a population
between the point of implantation and somite formation
(Mus: E4.5 to less than E8)

MP:0011097

complete embryonic
lethality between somite
formation and embryo
turning

death of all organisms of a given genotype in a population
between somite formation and the initiation of embryo
turning (Mus: E8 to less than E9)

MP:0011098

complete embryonic
lethality during
organogenesis

death of all organisms of a given genotype in a population
between embryo turning and the completion of
organogenesis (Mus: E9-9.5 to less than E14)

MP:0011099

complete lethality
throughout fetal growth
and development

death of all organisms of a given genotype in a population
between the completion of organogenesis and birth (Mus:
E14 to approximately E18.5)

MP:0011100

complete preweaning
lethality

death of all organisms of a given genotype in a population
between fertilization and weaning age (Mus:
approximately 3-4 weeks of age)

MP:0011101

partial prenatal lethality

the appearance of lower than Mendelian ratios of
organisms of a given genotype due to death of some, but
not all of the organisms between fertilization and birth
(Mus: approximately E18.5)

MP:0011102

partial embryonic lethality

the appearance of lower than Mendelian ratios of
organisms of a given genotype due to death of some, but
not all of the organisms within the embryonic period prior
to organogenesis (Mus: prior to E14)

MP:0011103

partial embryonic lethality
at implantation

the appearance of lower than Mendelian ratios of
organisms of a given genotype due to death of some, but
not all of the organisms at the point of implantation (Mus:
E4.5)

MP:0011104

partial embryonic lethality
before implantation

the appearance of lower than Mendelian ratios of
organisms of a given genotype due to death of some, but
not all of the organisms between fertilization and
implantation (Mus: E0 to less than E4.5)

MP:0011105

partial embryonic lethality
between implantation and
placentation

the appearance of lower than Mendelian ratios of
organisms of a given genotype due to death of some, but
not all of the organisms between the point of implantation
and the initiation of placentation (Mus: E4.5 to less than
E9)
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MP:0011106

partial embryonic lethality
between implantation and
somite formation

the appearance of lower than Mendelian ratios of
organisms of a given genotype due to death of some, but
not all of the organisms between the point of implantation
and somite formation (Mus: E4.5 to less than E8)

MP:0011107

partial embryonic lethality
between somite formation
and embryo turning

the appearance of lower than Mendelian ratios of
organisms of a given genotype due to death of some, but
not all of the organisms between somite formation and the
initiation of embryo turning (Mus: E8 to less than E9)

MP:0011108

partial embryonic lethality
during organogenesis

the appearance of lower than Mendelian ratios of
organisms of a given genotype due to death of some, but
not all of the organisms between embryo turning and the
completion of organogenesis (Mus: E9-9.5 to less than
E14)

MP:0011109

partial lethality throughout
fetal growth and
development

the appearance of lower than Mendelian ratios of
organisms of a given genotype due to death of some, but
not all of the organisms between the completion of
organogenesis and birth (Mus: E14 to approximately
E18.5)

MP:0011110

partial preweaning lethality

the appearance of lower than Mendelian ratios of
organisms of a given genotype due to death of some, but
not all of the organisms between fertilization and weaning
age (Mus: approximately 3-4 weeks of age)

MP:0011111

complete lethality during
fetal growth through
weaning

death of all organisms of a given genotype in a population
between the completion of organogenesis and weaning
age (Mus: E14 to approximately 3 weeks of age)

MP:0011112

partial lethality during fetal
growth through weaning

the appearance of lower than Mendelian ratios of
organisms of a given genotype due to death of some, but
not all of the organisms between the completion of
organogenesis and weaning age (Mus: E14 to
approximately 3 weeks of age)

MP:0011400

complete lethality

all individuals of a given genotype in a population die
before the end of the normal lifespan but time(s) of death
are unspecified

MP:0013292

embryonic lethality prior to
organogenesis

death prior to the completion of embryo turning (Mus:
E9-9.5)

MP:0013293

embryonic lethality prior to
tooth bud stage

death prior to the appearance of tooth buds (Mus: E12E12.5)

MP:0013294

prenatal lethality prior to
heart atrial septation

death prior to the completion of heart atrial septation
(Mus: E14.5-15.5)

E, embryonic day; Mus, Mus musculus.
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Table 2.2 Human orthologs of mutation-intolerant essential genes that are not
currently included in the catalogs of Mendelian disease genes.
Gene
ATP6V1B2

Chrom Start

End

RVIS percentile pLI percentile

8

20197367

20226819

21.6

9.6

CASC3

17

40140318

40172183

9.1

17.1

CASZ1

1

10636604

10796650

13.6

3.4

CHD4

12

6570083

6607476

0.7

0.6

COG3

13

45464898

45536630

17.9

5.7

CTR9

11

10750987

10779743

6.5

1.5

DCP2

5

112976702

113020970

22.0

19.7

DHX30

3

47802909

47850195

2.0

1.5

FOXJ3

1

42176539

42335877

21.3

12.1

MAT2A

2

85539165

85545280

19.3

23.7

MYO18A

17

29073517

29180412

12.8

5.3

NEMF

14

49782083

49853203

5.7

11.5

PRDM10

11

129899706

130002835

15.6

6.9

PREP

6

105277565

105403084

5.9

9.7

RSBN1

1

113761832

113812476

13.0

21.4

RUFY3

4

70704204

70807315

23.1

11.6

SMC5

9

70258962

70354888

9.7

11.7

SYNPO2

4

118850688

119061247

6.8

23.5

TMEM63B

6

44126914

44155519

5.5

4.1

ZMIZ2

7

44748581

44769881

4.9

4.9

ZNF496

1

247297412

247331846

19.9

11.2

ZNF536

19

30228290

30713538

1.1

13.5
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Table 2.3 Essentiality status of human disease genes categorized by phenotypic abnormality.

HPO ID

HP:0001197

Name
Abnormality of prenatal development
or birth

#

#

#

EGs

NEGs

Unknown

390

234

83

73

# Genes

OR1 95%CI

OR 95% CI

low

high

3.70

2.87

4.78

3.37E-27

OR

P value

HP:0000769

Abnormality of the breast

230

135

58

37

2.99

2.19

4.08

4.16E-13

HP:0003011

Abnormality of the musculature

1624

798

410

416

2.82

2.48

3.20

4.41E-60

HP:0040064

Abnormality of limbs

1194

639

327

228

2.74

2.38

3.15

2.38E-47

HP:0001608

Abnormality of the voice

215

114

55

46

2.65

1.92

3.67

1.47E-09

HP:0001507

Growth abnormality

1470

735

397

338

2.63

2.31

3.00

2.18E-50

HP:0002086

Abnormality of the respiratory system

1016

521

272

223

2.62

2.25

3.06

6.78E-37

HP:0000924

Abnormality of the skeletal system

1839

909

528

402

2.51

2.24

2.83

7.10E-56

HP:0000152

Abnormality of head or neck

1875

908

539

428

2.45

2.18

2.76

1.64E-53

HP:0025031

Abnormality of the digestive system

1542

760

443

339

2.43

2.15

2.76

2.32E-45

1418

700

422

296

2.32

2.04

2.64

1.36E-38

HP:0001626

Abnormality of the cardiovascular
system

HP:0000478

Abnormality of the eye

1755

825

522

408

2.25

2.00

2.53

8.36E-42

HP:0003549

Abnormality of connective tissue

867

432

259

176

2.23

1.90

2.62

1.65E-23

1435

687

429

319

2.23

1.96

2.53

4.39E-35

557

303

179

75

2.22

1.84

2.69

4.93E-17

HP:0000119
HP:0002664

Abnormality of the genitourinary
system
Neoplasm

48

HP:0000707

Abnormality of the nervous system

2336

1064

713

559

2.20

1.98

2.45

5.32E-49

HP:0000598

Abnormality of the ear

1273

605

380

288

2.18

1.91

2.50

3.07E-30

HP:0001574

Abnormality of the integument

1555

731

498

326

2.04

1.80

2.30

1.44E-30

HP:0002715

Abnormality of the immune system

1083

503

365

215

1.84

1.60

2.12

2.55E-17

827

385

279

163

1.81

1.55

2.13

2.62E-13

798

386

281

131

1.81

1.54

2.12

3.03E-13

1500

647

507

346

1.72

1.52

1.95

9.49E-18

HP:0001871
HP:0000818
HP:0001939

Abnormality of blood and bloodforming tissues
Abnormality of the endocrine system
Abnormality of
metabolism/homeostasis

HP:0025142

Constitutional symptom

394

173

156

65

1.41

1.13

1.76

0.0022

HP:0045027

Abnormality of the thoracic cavity

18

7

8

3

1.10

0.40

3.03

1
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Table 2.4 Tissue-specific essential genes.
Tissue

# Genes

Testis

27

Liver

15

Muscle

12

Kidney

8

Brain
Pituitary
Adrenal
Gland
Pancreas
Cells
Whole Blood
Thyroid
Small
Intestine
Heart
Lung
Nerve
Skin
Stomach
Spleen
Bladder
Colon
Prostate
Esophagus

7
6

Genes
LIN28A, DMBX1, FSHR, TRIM71, DPPA4, ZBTB20, NKX11, GCM2, GCM1, PKD1L1, PAX4, C7orf55, FGF8, UTF1,
SP7, FOXN4, RAD9B, POU4F1, HBZ, TEX19, SKOR2,
DCC, C19orf67, MED26, C21orf59, TBX22, PLAC1
SERPINC1, APOB, PROC, SLC2A2, FGG, CYP7A1, SAA2,
F2, CPB2, F7, CYP1A2, HP, APOH, SERPIND1, F9
AMPD1 ,CACNA1S, MYOG, NEB, CHRNA1, MYL1,
CHRNG, TAL2, MYF6, MYF5, ATP2A1, MYLPF
NPHS2, SLC34A1, KCNJ1, GDF3, AQP2, SLC12A1,
WNT9B, DNMT3L
OTP,CALCR,CHAT,FGF3,GSX1,RTL1,AVP
LMX1A,POMC,PROP1,LHX3,NEUROD4,RAX

6

STAR,CYP11B2,CYP17A1,PHOX2A,CYP11A1,MC2R

5
5
4
3

SPINK1,CLPS,PTF1A,IFITM5,INS
CR1L,COL10A1,T,HMX3,PPAN
F11R,HBB,KLF1,ALAS2
F11R,FOXE1,TSHR

3

FGF19,MEP1B,P2RY4

3
3
2
2
1
1
1
1
1
1

BMP10,MYL7,MYH6
SFTPB,CSF2,SFTPA1
TMEM8C,FGF4
HELT,KRT2
RFX6
SPIC
UPK2
SLC26A3
SP8
ERVFRD-1
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Supplementary data
Supplementary data 2.1 IMPC subviable genes with disease causing mutations in
HGMD.
Supplementary data 2.2 IMPC lethal genes with disease causing mutations in
HGMD.
Supplementary data 2.3 Catalog of EGs and NEGs.
Supplementary data 2.4 Enrichment of EGs among genes within each cytoband in
human genome build hg19.
Supplementary data 2.5 Enrichment of EGs among genes within each cytoband in
mouse genome build mm10.
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CHAPTER 3: Cumulative effect of deleterious variants in essential
genes on ASD risk
Introduction
Autism spectrum disorder (ASD) is a heterogeneous, heritable neurodevelopmental
syndrome characterized by impaired social interaction, communication, and repetitive
behavior (Huguet et al., 2013; State and Levitt, 2011). The highly polygenic nature of
ASD (de la Torre-Ubieta et al., 2016; De Rubeis and Buxbaum, 2015; Willsey and State,
2015) suggests that the analysis of the full spectrum of sequence variants in hundreds of
genes will be necessary for deeper understanding of disrupted neuronal function.
Prioritization of ASD risk genes initially focused on known pathways with recognized
relevance to pathogenesis of ASD, such as synaptic function and neuronal development
(Geschwind and Levitt, 2007). However, combined analyses of de novo, inherited, and
case–control variation in over 2,500 ASD parent–child nuclear families identified around
100 genes contributing to ASD risk (De Rubeis et al., 2014; Iossifov et al., 2014; Sanders
et al., 2015), converging on pathways implicated in transcriptional regulation and
chromatin modeling in addition to synaptic function. The early on-set of ASD suggests a
prenatal origin of ASD. Multiple lines of evidence implicated that impairments of early
brain development were involved in the pathogenesis of ASD (Parikshak et al., 2013;
Stoner et al., 2014; Willsey et al., 2013a).
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The main challenge in the current understanding of genetic architecture of ASD comes
from a need to study the interplay between variants with a high effect (for example,
recurrent de novo variants) and a background of variants with an intermediate effect but
nevertheless, which still disrupt proper neuronal development. Essential genes (EGs) or
genes that are necessary for successful completion of pre- and postnatal development are
prime candidates for the source of this background or load of variants with a cumulative
intermediate effect. EGs are highly enriched for human disease genes and under strong
purifying selection (Georgi et al., 2013; Petrovski et al., 2013; Zhang et al., 2011). In
addition to intolerance to loss-of-function , the functional impact of EGs is reflected by
haploinsufficiency that is commonly observed in heterozygous mutations (Deutschbauer
et al., 2005; Georgi et al., 2013). In addition to their role in defining a “minimal gene set”
(Koonin, 2003; Mushegian and Koonin, 1996), EGs tend to play important roles in
protein interaction networks (Hwang et al., 2009). Therefore, one may consider that EGs
are involved in rate-limiting steps that affect a range of disease pathways (Chakravarti
and Turner, 2016).
A deeper understanding of the mutational spectrum of EGs in a neurodevelopmental
disorder, such as ASD, is important, because EGs are less likely to be redundant, are
more likely to have functional consequences when mutated, and may produce a gradation
of phenotypes (White et al., 2013). Previous work by Georgi et al. reported an enrichment
of EGs among genes with de novo mutations in ASD patients (Georgi et al., 2013).
Several groups reported an enrichment of de novo and rare inherited single-nucleotide
loss-of-function variants in ASD probands (Iossifov et al., 2014; Krumm et al., 2015),
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although there is a depletion of damaging mutations in ASD risk genes in population
controls (Iossifov et al., 2015; Petrovski et al., 2013; Samocha et al., 2014). With the
most comprehensive list of human EGs to our knowledge, I extended the analysis to both
de novo and inherited damaging variants in 1,781 ASD families. In addition to disease
status, I further showed the effect of damaging variants in EGs on ASD-related traits,
such as the social skill measurement in 2,348 ASD probands. Finally, I performed
coexpression analysis of EGs in the developing human brain to identify clusters of
interacting EGs that contribute to ASD risk and suggest ASD candidate genes.
Results
Increased burden of deleterious mutations in essential genes in ASD probands
To address a possible cumulative effect of variants in EGs in ASD in a larger cohort of
1,781 ASD quartet families (with 1,781 probands and 1,781 siblings) from the Simons
Simplex Collection (Fischbach and Lord, 2010), I acquired de novo and rare inherited
mutations from the exome sequencing data of these families (Iossifov et al., 2014;
Krumm et al., 2015). I examined the individual mutational burden defined by the number
of de novo loss-of-function (dnLoF), de novo nonsynonymous damaging (dnNSD), and
inherited rare damaging (inhRD) mutations per individual (Supplementary data 3.1 and
3.2). On average, an ASD proband carried 0.06 dnLoF, 0.21 dnNSD, and 10.74 inhRD
mutations in EGs. The mutational burden in EGs was significantly elevated in ASD
probands compared with unaffected siblings for the three classes of variants considered
(P value = 4.75 × 10−7 for dnLoF, P value = 3.41 × 10−4 for dnNSD, and P value = 0.017
for inhRD; one-sided Wilcoxon signed ranked test) (Figure 3.1 and Table 3.1). In
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contrast, no significant difference in mutational burden in NEGs was observed (P value =
0.10 for dnLoF, P value = 0.069 for dnNSD, and P value = 0.75 for inhRD) (Table 3.1).
Interestingly, 10,823 genes that are currently not assigned as EG or NEG (i.e.,
phenotypically uncharacterized in mouse knockouts and human cell-based assays) have a
moderately elevated burden of dnLoF but not dnNSD and inhRD variants in ASD
probands (P value = 0.0042) (Table 3.1). Notably, the effect sizes of EG burden in each
variant type correspond to our understanding of the severity of the variant type; de novo
mutations, which are expected to have a larger functional impact, also display the
strongest difference between ASD probands and unaffected siblings (effect size = 0.117
for dnLoF; effect size = 0.079 for dnNSD; Cohen’s d). In contrast, inherited mutations
are expected to have a moderate functional impact, and a smaller difference is observed
between probands and siblings (effect size = 0.042 for inhRD). Although I observed
marginally increased burden of dnLoF and dnNSD mutations in EGs in female (n = 325)
compared with male (n = 2,043) probands (Table 3.2), the analysis of families divided by
gender of proband–sibling pairs (female–female, male–female, female–male, and male–
male) showed that gender bias does not underlie the observed differences in mutational
burden between probands and siblings (Table 3.3).
The effect of rare damaging mutations in essential genes on social and cognitive
impairments
To evaluate the effect of rare damaging mutations in EGs on ASD-associated traits, we
used the available quantitative phenotype data on social and cognitive impairments in
∼2,500 ASD families from Simons Simplex Collection (Iossifov et al., 2014; Krumm et
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al., 2015) (Supplementary data 3.3). As a measure of sociability, I used the total raw
score from the Social Responsiveness Scale (SRS) (Constantino and Gruber, 2005), and
as cognitive measures, I used three different intelligence quotient (IQ) scores (full-scale
IQ, verbal IQ, and nonverbal IQ). As previously reported (Constantino et al., 2003), SRS
scores were unrelated to IQ, especially in subjects with IQ higher than 50 (Figure 3.2). In
male probands, I observed that the mutational burden in EGs was positively correlated
with the SRS total raw score (P value = 1.08 × 10−6; Poisson regression) (Table 3.4). The
effect was not significant in NEGs (P value = 0.21). In female probands, mutational
burden in NEGs but not EGs was negatively correlated with SRS total raw score (P value
= 0.085 for EG and P value = 6.06×10-6 for NEG). In addition, I found that mutational
burden in both EGs and NEGs had a significant effect (P value < 2.2 × 10−16) on verbal
and nonverbal IQ scores and that the effect sizes of mutational burden in EGs and NEGs
were comparable (Table 3.5). These results suggest that, in ASD probands, deleterious
variants in EGs contribute to decreased social skills in males, whereas deleterious
variants in both EGs and NEGs lead to decreased IQ.
The overlap between essential genes and known ASD risk genes
To initially explore the overlap between EGs and known ASD genes, I examined the
essentiality status of ∼500 ASD candidate genes from the Simons Foundation Autism

Research Initiative (SFARI) AutDB database (updated December of 2015) (Abrahams et
al., 2013) (Figure 3.3). Compared with NEGs, EGs were enriched among ASD
candidates categorized as “syndromic” (category S: odds ratio = 3.95, P value = 0.0003;
two-sided Fisher’s exact test), candidates with “high confidence” (category 1: odds ratio
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= 15.12, P value = 0.0004), and candidates with “suggestive evidence” (category 3: odds
ratio = 2.14, P value = 0.0006). Trends of enrichment of EGs were also observed for
“strong candidates” (category 2: odds ratio = 1.62, P value = 0.21). I did not observe
enrichment of EGs among candidate genes with less supportive evidence (categories 4–
6).
To further address whether EGs contribute to ASD risk, I compared the strength of ASD
association signals between EGs and NEGs in data from a recent comprehensive analysis
of ASD genomic architecture (Sanders et al., 2015), where the transmission and de novo
association (TADA) test (He et al., 2013) was used to evaluate ASD association based on
combined evidence from de novo single nucleotide variants (SNVs), de novo small
deletions, and rare inherited variants from Simons Simplex Collection cohorts as well as
case–control data from Autism Sequencing Consortium (ASC) cohorts (Buxbaum et al.,
2012). There was a significant enrichment of EGs compared with NEGs in 65 highconfidence TADA ASD genes [TADA false discovery rate (FDR) q values < 0.1]
identified by Sanders et al. (Sanders et al., 2015) (36 EGs vs. 15 NEGs; odds ratio = 3.03,
P value = 1.82 × 10−4; one-sided Fisher’s exact test). In a broader set of 441 “potential”
TADA ASD genes (TADA FDR < 0.5), EGs were also enriched compared with NEGs
(132 EGs vs. 117 NEGs; odds ratio = 1.43, P value = 0.00537). Furthermore, by
comparing the observed TADA FDR with the expected TADA FDR, I detected a strong
deviation from the null distribution in EGs, especially in 132 EGs with potential ASD
association (TADA FDR < 0.5) (Figure 3.4). In contrast, NEGs were not enriched for
association relative to the background expectation, suggesting that the association signals
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between EGs and ASD were stronger and less likely to be false positive compared with
NEGs.
The spatio-temporal expression specificity of essential genes in human brain
To explore the spatio-temporal expression specificity of EGs in human brain, I performed
Cell type-Specific Expression Analysis (CSEA) (Xu et al., 2014) of EGs and NEGs based
on BrainSpan RNA-seq data across 6 brain regions and 10 developmental stages and
ages (Table 3.6). Strikingly, I observed distinct temporal patterns of expression
specificity between EGs and NEGs (Figure 3.6). In six brain tissue types (amygdala,
cerebellum, cortex, hippocampus, striatum and thalamus), EGs were enriched for genes
specifically expressed in brain at early developmental stages (from early to mid-fetal)
while NEGs were enriched for genes specifically expressed in brain at later stages (from
late fetal to young adulthood). For each set of EGs which were specifically expressed, I
evaluated the enrichment of 441 potential ASD genes (FDR < 0.5) from Sanders et al.
(Sanders et al., 2015) (Figure 3.7; Table 3.6). Significant enrichment was found in early
mid fetal cortex (p-value=2.17 ×10-6; One-sided Fisher’s exact test) and early mid fetal
striatum (p-value=1.77 ×10-4; One-sided Fisher’s exact test). This finding agrees with
recent studies using different approaches which suggested key brain regions involved in
the pathogenesis of ASD during early to mid-fetal development (Parikshak et al., 2013;
Willsey et al., 2013b; Xu et al., 2014). Moderate enrichment was also found in early fetal
cortex, early fetal cerebellum and late mid fetal cortex. In contrast, specifically expressed
NEGs showed no enrichment.
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Coexpression modules in the developing human brain
It is our hypothesis that a cumulative effect of deleterious variants in several EGs, within
the same pathway or across pathways may underlie impaired brain development and
individual’s ASD risk. To identify clusters of potentially interacting genes, I evaluated
the spatiotemporal expression of EGs and NEGs using RNA sequencing (RNA-seq) data
from BrainSpan . I identified 41 coexpression modules with distinct expression patterns
across 16 brain regions and 31 pre- and postnatal time points (Figure 3.8). I observed that
the majority of EG-enriched modules (11 of 14; FDR < 0.1; two-sided Fisher’s exact test)
(Figure 3.8 and 3.9; Table 3.7) exhibited an “early-expression” pattern, where the
expression levels were higher at early fetal stages (starting from 8 postconceptual weeks)
and gradually declined before birth. In contrast, the majority of the NEG-enriched
modules (15 of 18) exhibited a “later-expression” pattern, with expression levels that
were lower at early fetal stages and gradually increased until birth.
I found that EGs in three EG-enriched modules (M01, M02, and M16) were significantly
enriched (FDR < 0.1; one-sided Fisher’s exact test) for 441 potential TADA ASD genes
(Figure 3.9). Notably, all of the three modules were also EG-enriched and earlyexpressed across fetal brain regions (Figure 3.9 and 3.10). From the pathway enrichment
analysis of these EG-enriched modules in the Reactome database (Croft et al., 2014;
Fabregat et al., 2016), I found that the top pathways enriched included “transcription”
(M01), “chromatin modifying enzymes and chromatin organization” (M02), and “axon
guidance” (M16) (Table 3.8), in agreement with the insights from recent large-scale
autism studies showing that genes for synaptic formation, transcriptional regulation, and
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chromatin remodeling are disrupted in autism (De Rubeis et al., 2014; Iossifov et al.,
2014; Sanders et al., 2015). This combined analysis identified 974 EGs from three
modules that are coexpressed with known ASD candidate genes at distinct stages of brain
development.
29 essential genes as strong candidates for ASD
To further prioritize known EGs as candidates for ASD, I constructed a coexpression
network for 974 EGs from three modules enriched for potential ASD genes (Figure 3.10);
844 genes among 974 have a close interaction with high-confidence ASD genes
(connected to at least two genes with TADA FDR < 0.1), and 370 genes harbor de novo
or inherited loss-of-function mutations in ASD individuals from Simons Simplex
Collection or ASC cohorts. Of these, 52 have a TADA FDR less than 0.5. Among 52
genes, 23 have been previously shown to contribute to ASD risk [categories syndromic
(S), 1, 2, 3, and 4 in SFARI]. For the remaining 29 EGs that have not yet been linked to
ASD risk, I argue that, based on (i) the importance of EGs in ASD etiology as shown by
their role in critical developmental stages and the increased burden of rare, damaging
mutations in ASD individuals; (ii) their coexpression with high-confidence ASD genes in
brain; and (iii) the suggestive genetic evidence from the TADA analysis, these 29 EGs
represent the strongest candidates for additional investigation in their role in ASD (Figure
3.11 and Table 3.8). According to available mouse phenotypes from the MGI (Eppig et
al., 2005) and the IMPC (Koscielny et al., 2014), 11 of these 29 EGs have reported
heterozygous phenotypes in mice (Table 3.9). Among them, four EGs (CHD1, FBXO11,
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KDM4B, and VCP) have been associated with abnormal neural development and/or
behavioral phenotypes in heterozygotes.
Discussion
I provided multiple lines of evidence suggesting that deleterious variants in EGs have a
cumulative effect on ASD risk. Using a comprehensive list of 3,915 EGs, I showed that
there is both an elevated burden of damaging mutations in EGs in ASD probands and also
an enrichment of EGs in the recently identified high-confidence ASD-associated genes.
Moreover, the analysis of EGs in the developing brain identified clusters of coexpressed
EGs implicated in ASD, including 29 EGs functionally related to previously identified
ASD risk genes.
I find that ASD individuals have a higher burden of mutations in EGs compared with
their unaffected siblings. It is notable but not surprising that this effect is particularly
pronounced when considering de novo mutations, because this class of mutations is only
subject to selection pressure after originating in the individual, and has exhibited some of
the most prominent associations with the risk of ASD (Iossifov et al., 2014; Iossifov et
al., 2012; O'Roak et al., 2012b; Sanders et al., 2012) . Similarly, a moderately increased
burden of dnLoF variants in ASD probands was detected with a group of 10,823
phenotypically uncharacterized genes. Based on current estimates, one-fifth of these
uncharacterized genes (∼2,000) are expected to be EGs, which may explain the higher
mutational burden of dnLoF variants in ASD probands. Recent studies have begun to
show that additional genetic factors, such as rare and common inherited variations, also
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contribute to ASD (Gauglerl et al., 2014; Krumm et al., 2015). My results support this
finding, showing that inherited, rare, damaging mutations in EGs also have a significant
effect on ASD risk. Furthermore, I show an EG-specific effect on social responsiveness, a
measure of the social aspects of ASD. In contrast, mutational burden in both EGs and
NEGs has an effect on IQ measures. Complex social behaviors result from a range of
different cognitive processes; however, in ASD subjects, there is a striking dissociation in
the level of impairment in social interaction or communication and general cognitive
abilities (as measured by IQ) (Constantino et al., 2003). Moreover, studies in model
organisms clearly show a fetal origin for social behavior deficits (Belinson et al., 2016).
My results are in line with these findings and suggest that, although a higher mutational
burden over all genes may have consequences on IQ, mutational burden in a set of genes
with a role at critical early developmental stages influences the development of social
behavior. Moreover, my findings are also further supported by the recent report that
genomic regions that are under accelerated evolution have essential functions in the
human brain development and, when mutated, may cause increased risk for autism (Doan
et al., 2016). Therefore, understanding the regulatory landscape of dosage-sensitive EGs
expressed at critical stages of brain development may reveal risk alleles for many
neurodevelopmental and psychiatric disorders.
The analysis of the overlapping set of Simons Simplex Collection ASD families by
several groups using complementary approaches led to the identification of around 100
ASD risk genes and the finding of a depletion of damaging mutations in ASD risk genes
(Iossifov et al., 2015; Petrovski et al., 2013; Samocha et al., 2014). I show that a
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significant number of reported ASD risk genes are essential for survival and fitness and
therefore have a distinctive mutational spectrum, providing a biological foundation for
this intolerance to damaging mutations. Of the spectrum of existing alleles, homozygosity
or compound heterozygosity for loss-of function alleles will never be observed. Also,
because of synthetic lethality, some combinations of mutations in EGs are eliminated.
Therefore, individuals will have only a subset of “milder” coding or regulatory alleles.
The current list of candidate genes consists of 100 (high-confidence ASD genes) to 400
genes (potential ASD genes) (Sanders et al., 2015). It is striking that my study provides
strong statistical evidence for the aggregate effect across 3,915 EGs impacting risk for
this neurodevelopmental disorder. A recent SNP-based heritability study reported the
extreme polygenicity of schizophrenia, with 70% of 1-Mb genomic regions harboring
schizophrenia risk alleles (Loh et al., 2015). Assuming a similar genetic architecture in
ASD and schizophrenia, genomic maps of EGs with “surviving” deleterious and
regulatory variants in ASD probands represent a complementary approach for the
analysis of combinations of culprit genes or alleles.
Because of the fundamental functional role of EGs in an organism, genetic variants in
these genes are likely to contribute to many traits and diseases as reflected by the
previous finding that EGs are enriched for human disease genes (Dickerson et al., 2011;
Dickinson et al., 2016; Georgi et al., 2013). My study is focused on a specific
neurodevelopmental disorder—ASD—because it has been suggested that ASD has its
roots in abnormalities in prenatal brain development (Hazlett et al., 2017; Parikshak et
al., 2013; Stoner et al., 2014; Willsey et al., 2013a). Specifically, my analysis of the
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temporal expression patterns of coexpressed gene modules in the developing brain shows
that genes in three EG-enriched coexpression modules implicated in ASD are expressed
at a high level at the earliest stages of brain development, as early as 8 weeks after
conception. In contrast, at later stages of brain development, the expression levels of
genes in these EG-enriched modules decrease, whereas the expression levels of genes in
NEG-enriched modules increase. The potential role of EGs in ASD is further supported
by the analysis of the spatio-temporal expression specificity of essential genes in human
brain, which showed that EGs specifically expressed in brain tissues converged at key
brain regions (including cortex and striatum) involved in the pathogenesis of ASD
(Parikshak et al., 2013; Willsey et al., 2013b; Xu et al., 2014) during early to mid-fetal
development. These findings suggest that EGs have a distinctive influence at some of the
earliest brain developmental stages as previously reported for constrained genes (Choi et
al., 2016) and genes in functional networks perturbed in ASD (Chang et al., 2015).
However, to further confirm the distinct contribution of EGs to early onset diseases, a
comparison of the burden of deleterious variants in EGs across other complex disorders,
including those with a later onset, is warranted.
Each individual can carry a number of deleterious mutations, each of which can have a
small effect. Because brain function may be particularly sensitive to mutation
accumulation, identifying a specific set of genes in which mutations have a behavioral
effect will assist us in understanding how mutation accumulation within an individual can
result in a phenotype, such as ASD. Hallmarks of ASD are phenotypic heterogeneity,
frequent comorbidities, and that no specific brain region or cell type is uniquely
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implicated (de la Torre-Ubieta et al., 2016), further supporting the role of genes with a
global effect on embryonic and fetal development. Here, I provide evidence that genes
that are essential for survival and fitness also contribute to ASD risk and lead to the
disruption of normal social behavior.
Materials and Methods
Burden analysis of mutations in EGs in ASD families
The Simons Simplex Collection contains genetic and phenotypic information from 2,600
ASD families, each of which has one child affected with ASD and unaffected parents and
siblings (Fischbach and Lord, 2010). ASD probands were defined by clinical consensus
from the Autism Diagnostic Interview–Revised (Lord et al., 1994) and the Autism
Diagnostic Observation Schedule (Lord et al., 2000). Multiple individual phenotypic
measures, including the Social Responsiveness Scale (SRS) (Constantino and Gruber,
2005) and IQ, were available (Iossifov et al., 2014; Krumm et al., 2015) .
I aimed to investigate the impact of both de novo and rare inherited variants in EGs on
ASD risk. I acquired a list of 5,648 de novo variants from an exome sequencing study on
2,517 ASD families from the Simons Simplex Collection (Iossifov et al., 2014) and an
additional list of 1,544 de novo variants from a reanalysis of the same cohort (2,377 ASD
families) with a different pipeline (Krumm et al., 2015). Among 7,192 de novo variants,
674 were loss-of-function mutations (i.e., SNVs that are frameshift, stop-loss, stop-gain,
start-loss, splicing donor or acceptor, and frameshift indels), and 3,462 were
nonsynonymous mutations (i.e., missense SNVs and nonframeshift indels). The
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deleterious de novo nonsynonymous mutations were selected using a threshold of the
Combined Annotation-Dependent Depletion (CADD) (Kircher et al., 2014) phred-scale
score above 10. In addition, I obtained 249,729 rare inherited mutations from 2,377 ASD
families (Krumm et al., 2015). From the variants successfully called by both GATK
(McKenna et al., 2010) and FreeBayes (Garrison and Marth, 2012), I extracted loss-offunction mutations and nonsynonymous mutations with minor allele frequency in Exome
Variant Server (European ancestry) less than 0.01 and CADD phred-scale score above
10. At the end of the variant filtering steps, I obtained 372 dnLoF variants, 1,497 dnNSD
variants, and 77,891 inhRD variants in EGs or NEGs for mutational burden analysis
(Supplementary data 3.1 and 3.2).
The individual mutational burden was defined as the number of mutations carried by each
subject in the gene sets of interest (i.e. 3,915 EGs and 4,919 NEGs) for each class of
variants (dnLoF, dnNSD, and inhRD). Among all Simons Simplex Collection ASD
families, there were 1,781 ASD quartets where exome sequence data from an affected
proband and an unaffected sibling were available. The individual mutational burden in
1,781 ASD probands was compared with the burden in their unaffected sibling using onesided Wilcoxon signed ranked test. The effect sizes were represented by cohen’s D. The
95% confidence interval of effect size was estimated by a bootstrapping procedure, i.e.
the 2.5 percentile and 97.5 percentile of the pool of effect sizes from 1000 resampled data
sets generated from the original data set. In each resampled data set, the pairs of siblings
were randomly selected with replacement.
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I acquired SRS total raw scores for 2,348 probands and 1,678 siblings as well as
verbal/nonverbal IQs for 2,359 probands for 1,781 ASD quartets and 587 ASD trios from
Simons Simplex Collection families (Supplementary data 3.3). Poisson regression
analysis was carried out separately between each trait (i.e., SRS total raw score and
verbal IQ and nonverbal IQ) as the dependent variables and the individual burdens of all
rare damaging mutations (including dnLoF, dnNSD, and inhRD) in EGs or NEGs as the
independent variables.
Comparison between observed and expected TADA FDR q values
To compare the strength of association signals to ASD between EGs and NEGs, FDR q
values for the TADA test of 18,665 genes were obtained from the work by Sanders et al.
(Sanders et al., 2015). For each gene set of interest (i.e., 3,915 EGs or 4,919 NEGs), the
null distribution of the transmission and de novo association test (TADA) (He et al.,
2013) FDR q values was generated by randomly resampling with replacement. Within
one iteration of the resampling procedure, the TADA FDR q value of a random gene
from the tested 18,665 genes was obtained for each gene in the gene set of interest. The
resampled TADA FDR q values were then ranked from low to high. The resampling
procedure was repeated for 100,000 iterations. For each observed TADA FDR q value
ranked from low to high, the median of 100,000 resampled q values with the same rank
was considered the expected TADA FDR q value. The 2.5th and 97.5th percentiles of
100,000 resampled q values were considered the estimated 95% confidence intervals of
each expected TADA FDR q value. The observed FDR q values were then compared
with the expected FDR q values.
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Construction of Coexpression Modules and Coexpression Network in Brain
Coexpression analysis in human brain was conducted based on RNA-seq data from
BrainSpan: Atlas of the Developing Human Brain . We used the Weighted Correlation
Network Analysis (WGCNA) package (Langfelder and Horvath, 2008) for data quality
control and identification of modules of coexpressed genes. The expression data for
52,376 Ensembl genes (Flicek et al., 2014) (including protein-coding genes, noncoding
genes, or pseudogenes) across 525 samples were obtained; 1,716 genes with too many
missing entries or zero variance in expression levels were removed by the “goodSamplesGenes” function in the WGCNA, and 12,613 genes with very low expression
levels [maximum reads per kilobase of transcript per million mapped reads (RPKM) less
than 0.5 across samples] were removed. As a final step for gene-level data cleaning, only
protein-coding genes were selected for additional analysis. For sample-level data
cleaning, three outlier subjects (300, 303, and 306) were removed according to subjectlevel clustering result. Ten brain tissue types (caudal ganglionic eminence, cerebellum,
dorsal thalamus, lateral ganglionic eminence, medial ganglionic eminence, occipital
neocortex, parietal neocortex, primary motor sensory cortex, temporal neocortex, and
upper rhombic lip) with data from fewer than 10 developmental stages were removed.
The final quality-controlled dataset consisted of expression levels of 15,952 proteincoding genes in 16 brain tissue types across 31 pre- and postnatal developmental stages
(495 samples in total). For module detection, we used the “blockwiseModules” function
in the WGCNA with default parameters, except for the network type (power = 6,
deepSplit = 2, and networkType = “signed”). I used the signed version of coexpression
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analysis that links two genes with positive correlation of expression levels. Coexpression
between gene pairs was calculated based on the quality-controlled BrainSpan RNA-seq
data with 495 brain samples. Two genes were defined as “coexpressed” in the brain if the
Pearson correlation of the expression levels of both genes across 495 brain samples was
greater than or equal to 0.8. In total, there were 8,600,150 coexpression links among
protein-coding genes. The coexpression network was created using the GeneMania
plugin (Mostafavi et al., 2008) within Cytoscape 3.2.1 (Shannon et al., 2003). Of 974
EGs from three modules (M01, M02, and M16) implicated in ASD, coexpression data
were available for 973 genes, which were used as the input gene set for network
construction. The coexpression network consists of a main connected component with
963 nodes and 187,443 edges as well as 10 isolated nodes.
Pathway enrichment analysis
I performed pathway enrichment analysis in the Reactome database (Fabregat et al.,
2016) using Enrichr (Chen et al., 2013) for three EG-enriched modules (M01, M02, and
M16) that were also enriched for potential ASD genes. The enriched pathways were
ranked by P values with Benjamini–Hochberg adjustment [False discovery rate (FDR) q
values] from the Fisher’s exact test.
The cell type-specific expression analysis (CSEA)
The cell type-specific expression analysis (CSEA) was performed using the SEA on-line
tool ( http://genetics.wustl.edu/jdlab/csea-tool-2/) (Xu et al., 2014) with lists of 3,915
EGs and 4,919 NEGs as input, among which the SEA analysis were available for 3,838
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EGs and 4,757 NEGs. The returned p-values and lists of enriched genes with the
threshold of specificity index thresholds (pSI) < 0.05 were used for analysis.
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Figures

Figure 3.1 Individual mutational burden analysis in 1,781 pairs of ASD probands
and unaffected siblings. The analyses were performed separately for 3,915 EGs (red)
and 4,919 NEGs (turquoise). The individual mutational burden is defined by the number
of dnLoF, dnNSD, and inhRD mutations per individual. Effect sizes were measured by
Cohen’s d, which is defined as the difference between both means divided by the SD of
the paired differences. The estimated 95% confidence intervals of effect sizes were
plotted. P values were obtained from one-sided Wilcoxon signed ranked test. *P value <
0.05.
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Figure 3.2 Correlation between SRS and IQ. For each of 2,368 ASD probands from
Simons Simplex Collection, the Pearson correlation between SRS total raw scores and
three IQ scores (full-scale IQ, verbal IQ, and nonverbal IQ) was plotted. The probands
were divided by IQ scores: (A, C, and E) IQ< 50 and (B, D, and F) IQ ≥ 50.
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Figure 3.3 Essentiality statuses of SFARI ASD candidate genes. ASD candidate genes
categorized by SFARI genes scores [S (syndromic); 1, high confidence; 2, strong
candidate; 3, suggestive evidence; 4, minimal evidence; 5, hypothesized; and 6, not
supported] (Abrahams et al., 2013) and their essentiality status (EG in red, NEG in
turquoise, and unknown in gray). ***The P value from two-sided Fisher’s exact test (EG
vs. NEG) is less than 0.001.
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Figure 3.4 The distribution of TADA FDR q values of EGs and NEGs. The FDR q
value of the TADA test evaluates ASD association based on combined evidence from de
novo SNVs and small deletions, rare inherited variants, and variants (9). The observed
negative log10 (q) values of 3,915 EGs (red) and 4,919 NEGs (turquoise) are compared
with the expected counterparts under the null hypothesis. The dashed lines indicate the
FDR thresholds (FDR = 0.1 in red and FDR = 0.5 in blue) for identification of ASD risk
genes. The 95% confidence intervals of the expected negative log10 (q) values are shaded
in gray.
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Figure 3.5 Expression profiles of 41 coexpression modules in the brain. Expression
profiles of genes from 41 coexpression modules based on the RNA-seq data from
BrainSpan are shown. The y axis represents the first principle component of the modulelevel expression profiles in each brain tissue type. The x axis represents developmental
stages in chronological order (Figure 3.7 shows the labels of the time points). The vertical
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dashed lines indicate the time of birth. The total number of protein-coding genes in each
module (n) is indicated along with the module name.
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Figure 3.6 Spatio-temporal specific expression of essential genes and non-essential
genes. The sizes of dots indicate –log10 of p-values from the specific expression analysis
(SEA) on-line tool ( http://genetics.wustl.edu/jdlab/csea-tool-2/) (Xu et al., 2014) for
3,915 EGs (in red) and 4,919 NEGs (in turquoise) separately. Each number below red
dots indicate the number of specifically expressed EGs in the corresponding brain tissue
(x axis) and developmental stage (y axis).
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Figure 3.7 Enrichment for potential ASD genes among region- and time-specifically
expressed EGs. The heatmap shows the negative log10(p) values for enrichment of 441
potential ASD risk genes (Sanders et al., 2015) in each set of EGs specifically expressed
in each brain region (on the x-axis) and developmental stage (on the y-axis). The negative
log10 (p) values for combinations of brain regions and developmental stages with
significant enrichment of potential ASD genes (p-value<0.05 with Bonferroni correction;
one-sided Fisher’s exact test) are noted.
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Figure 3.8 Coexpressed modules enriched in EGs and NEGs. The upper barplot
displays the level of enrichment of EGs vs. NEGs for each of 41 coexpression modules
based on BrainSpan RNA-seq data. The lower barplot displays the level of enrichment
(green) of 441 potential ASD genes in EGs from 41 coexpression modules. The heights
of the bars represent negative log10 (FDR q value). The upper and lower red dashed lines
indicate FDR q value threshold of 0.1.
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Figure 3.9 The brain expression trajectories of genes from three coexpression
modules implicated in ASD. The expression trajectories in brain for 1,601 genes in M01
(orange), 1,150 genes in M02 (purple), and 347 genes in M16 (green) were fitted based
on the first principle components of the module level expression profiles (y axis). The x
axis represents developmental stages in chronological order. The vertical dashed line
indicates the time of birth. pcw, Postconceptual week.
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Figure 3.10 Co-expression network of essential genes from three modules implicated
in ASD. Coexpression network of 973 of 973 EGs from M01 (orange), M02 (purple), and
M16 (green). Edges indicate coexpression between gene pairs.
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Figure 3.11 Chromosomal distribution of 29 EGs suggested as strong ASD
candidate genes. The locations of each gene along the chromosomes are shown in red.
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Tables
Table 3.1 Mutational burden analysis in 1,781 ASD quartet families.
Variant
Type

dnLOF

dnNSD

Gene Set

Proband
Average

Sibling
Average

Effect Size

Effect Size
95% CI Low

Effect Size
95% CI High

p-value

EG Ji et al. (current publication)
EG Dickinson et al. (ref. 14)

3915

0.0640

0.0286

0.1170

0.0715

0.1596

4.75E-07

3326

0.0595

0.0253

0.1176

0.0730

0.1603

4.16E-07

EG Georgi et al. (ref. 11)

2472

0.0494

0.0168

0.1254

0.0820

0.1671

7.82E-08

human cell-EGs (ref. 20, 21, 22)

956

0.0079

0.0056

0.0193

-0.0269

0.0637

0.2118

NEG
Phenotypically uncharacterized
genes
EG Ji et al. (current publication)
EG Dickinson et al. (ref. 14)

4919

0.0387

0.0309

0.0300

-0.0157

0.0774

0.1028

10823

0.0752

0.0533

0.0606

0.0143

0.1084

0.004257

3915

0.2061

0.1589

0.0794

0.0324

0.1274

3.41E-04

3326

0.1875

0.1376

0.0892

0.0429

0.1353

8.13E-05

EG Georgi et al. (ref. 11)

2472

0.1505

0.1050

0.0895

0.0435

0.1366

7.36E-05

human cell-EGs (ref. 20, 21, 22)

956

0.0371

0.0365

0.0021

-0.0435

0.0499

0.4696

NEG
Phenotypically uncharacterized
genes
EG Ji et al. (current publication)
EG Dickinson et al. (ref. 14)

4919

0.1611

0.1404

0.0374

-0.0100

0.0827

0.0691

10823

0.2471

0.2791

-0.0419

-0.0884

0.0044

0.9636

3915

10.7428

10.6042

0.0420

-0.0041

0.0887

0.01688

3326

9.3257

9.2358

0.0287

-0.0185

0.0757

0.04139

2472

7.0236

6.9163

0.0402

-0.0053

0.0867

0.02622

EG Georgi et al. (ref. 11)
inhRD

#
Genes

human cell-EGs (ref. 20, 21, 22)

956

2.3745

2.3779

-0.0022

-0.0485

0.0435

0.5935

NEG
Phenotypically uncharacterized
genes

4919

12.7816

12.8355

-0.0150

-0.0618

0.0308

0.7456

10823

20.3947

20.4559

-0.0133

-0.0592

0.0342

0.5404
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Table 3.2 Difference in individual mutational burden between male and female
probands.

Variant
Type

Gene
Set

Female
Proband
Average

Male
Proband
Average

Effect
Size

p-value

EG

0.0862

0.0597

0.1042

0.0355

NEG

0.0462

0.0357

0.0551

0.1782

EG

0.2400

0.1948

0.1014

0.0388

NEG

0.2000

0.1596

0.0993

0.0742

EG

11.0523

10.9633

0.0151

0.4711

NEG

13.2677

13.0113

0.0360

0.5271

dnLoF

dnNSD

inhRD
Effect sizes were measured by Cohen's d, which is defined as the difference between both
means divided by pooled standard deviation. P-values with statistical significance are in
bold.
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Table 3.3 Mutational burden analysis in ASD probands and unaffected siblings
(dissected by the genders of proband-sibling pairs).
Variant
Type

Gene
Set

EG

dnLoF

NEG

EG

dnNSD

NEG

EG

inhRD

NEG

Proband
Gender
All
Female
Male
Male
Female
All
Female
Male
Male
Female
All
Female
Male
Male
Female
All
Female
Male
Male
Female
All
Female
Male
Male
Female
All
Female
Male
Male
Female

Sibling
Gender
All
Male
Female
Male
Female
All
Male
Female
Male
Female
All
Male
Female
Male
Female
All
Male
Female
Male
Female
All
Male
Female
Male
Female
All
Male
Female
Male
Female

#
Proband Sibling
Effect
Families Average Average Size
p-value
1781
0.0640
0.0286
0.1170 4.75×10-7
101
0.0891
0.0099
0.2588
0.0067
826
0.0593
0.0327
0.0893
0.0053
732
0.0615
0.0246
0.1228
0.0005
122
0.0902
0.0410
0.1461
0.0600
1781
0.0387
0.0309
0.0300
0.1028
101
0.0396
0.0297
0.0374
0.3884
826
0.0412
0.0266
0.0558
0.0549
732
0.0369
0.0314
0.0213
0.2838
122
0.0328
0.0574
0.0818
0.8302
1781
0.2061
0.1589
0.0794
0.0003
101
0.2178
0.1683
0.0724
0.2392
826
0.2094
0.1755
0.0552
0.0454
732
0.1885
0.1270
0.1136
0.0013
122
0.2787
0.2295
0.0725
0.2157
1781
0.1611
0.1404
0.0374
0.0691
101
0.1881
0.1980
0.0155
0.5696
826
0.1465
0.1477
0.0022
0.5515
732
0.1667
0.1175
0.0904
0.0080
122
0.2049
0.1803
0.0379
0.3817
1781 10.7428 10.6042
0.0420
0.0169
101 10.3762 10.6436
0.0778
0.8260
826 10.8341 10.7034
0.0401
0.1120
732 10.5765 10.4372
0.0417
0.0449
122 11.4262 10.9016
0.1619
0.0430
1781 12.7816 12.8355
0.0150
0.7456
101 12.5050 13.0792
0.1398
0.9143
826 12.8693 13.0182
0.0424
0.7802
732 12.6134 12.5546
0.0165
0.5576
122 13.4262 13.0820
0.0907
0.1327

Effect sizes were measured by Cohen's d, which is defined as the difference between both
means divided by the standard deviation of the paired differences. P-values were obtained
from one-sided Wilcoxon signed rank test.
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Table 3.4 Relationship between individual mutational burden and social
responsiveness scale in ASD probands.

Group

Gene Set

Estimate

Std. Error

p-value

2031 male

EG (3915 genes)

0.001860

0.000381

1.08×10-6

probands

NEG (4919 genes)

0.000407

0.000324

0.209

317 female

EG (3915 genes)

-0.001511

0.000877

0.085

probands

NEG (4919 genes)

-0.003084

0.000682

6.04×10-6

Coefficients for Poisson regression are shown, which modeled the relationship between
SRS total raw score and individual burden of all rare damaging mutations (including
dnLOF, dnNSD and inhRD mutations). The p-value with statistical significance with
positive estimated effects (p-value<0.05, estimate>0) is in bold.
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Table 3.5 Relationship between individual mutational burden and IQ in ASD
probands.

Trait

Gene Set
Estimate Std. Error p-value
EG (3915 genes) -0.007279 0.000400 <2.2×10-16
Verbal IQ
NEG (4919 genes) -0.005307 0.000383 <2.2×10-16
EG (3915 genes) -0.007172 0.000336 <2.2×10-16
Nonverbal IQ
NEG (4919 genes) -0.004906 0.000320 <2.2×10-16
Coefficients for Poisson regression are shown, which modeled the relationship between
verbal/nonverbal IQ and individual burden of all rare damaging mutations (including
dnLOF, dnNSD and inhRD mutations).
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Table 3.6 The spatio-temporal expression specificity of essential genes in human brain.
Tissue

Stage

p-value
Genes

#
Genes

#
pASD

OR
pASD

p-value
pASD

pASD list

Early Mid
Fetal
Early Mid
Fetal
Late Mid
Fetal

0.01

182

17

4.28

2.17E-06

0.015

142

12

3.80

0.00018

1

109

9

3.68

0.0013

Cerebell
um

Early Fetal

3.77E-06

239

14

2.56

0.0021

Cortex

Early Fetal

1.72E-16

348

18

2.25

0.0022

Early Fetal

4.33E-08

271

13

2.06

0.0151

Late Mid
Fetal

1

113

7

2.69

0.0200

TGM1,TRIO,ADNP,NR2F1,PRPF39,TBR1,WNT9A

Early Fetal

2.60E-28

375

16

1.83

0.0209

CHD1,NFIB,NFIA,PPM1D,PTK7,TCF3,WHSC1,NR2F1,TBR1,MIB1,
TTK,POLD1,ILF2,ERI1,KDM5B,WNT7B

Cortex
Striatum
Cortex

Thalam
us
Amygda
la
Hippoca
mpus
Striatum
Amygda
la
Cortex
Cerebell
um
Cerebell
um
Hippoca
mpus
Amygda
la

NFIB,TRIO,NFIA,ADNP,NUAK1,BCL11A,TBR1,TANC2,GRIN2B,KD
M4B,JUP,LDB1,KDM6B,DSCAM,SUV420H1,KDM5B,PBX1
TRIO,DNMT3A,BCL11A,TANC2,RAI1,LDB1,FOXP1,RELN,KDM6B,
SUV420H1,KDM5B,PBX1
TRIO,PRPF39,TBR1,SYNGAP1,ANK2,JUP,PTMS,WNT9A,KDM6B
TRIO,FOXP1,ADNP,NR2F1,RFX7,BCL11A,SIX2,PAX5,JUP,DNMT3
A,KDM6B,SUV420H1,KDM5B,WNT7B
TBR1,CHD1,NFIA,PPM1D,TCF3,NFIB,NUAK1,RFX7,BCL11A,MIB
1,SIX2,ERI1,TTK,POLD1,KDM6B,TANC2,KDM5B,PBX1
CTNNB1,DNMT3A,WHSC1,RFX7,NR2F1,TCF7L2,TTK,JUP,SMARC
E1,RNF38,NUAK1,KDM5B,PBX1

Late Mid
Fetal
Early Mid
Fetal
Neotal Early
Infancy

1

131

7

2.30

0.0402

FOXP1,BCL11A,RAI1,ETV2,PTMS,KDM6B,DNMT3A

1.13E-27

286

12

1.79

0.0463

NFIB,DNMT3A,TCF3,WHSC1,RFX7,NR2F1,TBR1,TTK,POLD1,LDB
1,KDM6B,PBX1

1

58

4

3.01

0.0516

SYNGAP1,DSG3,SHANK2,PLCB1

Late Infancy

1

174

8

1.96

0.0614

TGM1,PRPF39,PPM1D,INTS6,ETV2,PTMS,RELN,RIMS1

Late Fetal

0.231

148

7

2.02

0.0685

NFIB,NFIA,PTK7,CTNNB1,RELN,OVOL1,WNT7B

Early Mid
Fetal

2.61E-20

199

8

1.70

0.1110

NFIB,NFIA,ETV2,PTK7,TCF3,TBR1,TTK,KDM5B

Early Fetal

1.05E-28

344

12

1.47

0.1320

PPM1D,ADNP,TCF3,WHSC1,RFX7,NR2F1,TTK,POLD1,DNMT3A,S
MARCE1,KDM5B,ILF2

89

Cerebell
um
Cerebell
um
Thalam
us
Thalam
us
Hippoca
mpus
Cerebell
um

5.54E-11

312

11

1.49

0.1376

CHD1,NFIB,PTK7,TCF3,TGM1,TTK,EP400,RELN,OVOL1,DSCAM,
WNT7B

1

183

7

1.61

0.1564

TGM1,NFIA,PPM1D,SCN2A,RELN,ATP1A1,RIMS1

1

118

5

1.79

0.1582

ACHE,WNT9A,RIMS1,TCF7L2,SCN1A

1

58

3

2.21

0.1653

SCN1A,TCF7L2,RGMA

1

89

4

1.91

0.1692

PLVAP,NR3C2,WNT9A,NFIB

1.15E-11

271

9

1.39

0.2118

PLVAP,DNMT3A,PTK7,TCF3,JUP,RELN,WNT9A,LAMB1,WNT7B

1

100

4

1.69

0.2235

PLCB1,SCN1A,TBR1,NUAK1

1

73

3

1.73

0.2595

PLCB1,SCN1A,NUAK1

1

147

5

1.42

0.2840

TGM1,SCN2A,RELN,ATP1A1,RIMS1

1

113

4

1.48

0.2925

NR2F1,WNT9A,TCF7L2,RGMA

1

151

5

1.39

0.3028

TGM1,SCN2A,RELN,ATP1A1,RIMS1

Adolescence

1

158

5

1.32

0.3361

TGM1,SCN2A,RELN,ATP1A1,RIMS1

Cortex

Middle Late
Childhood

1

50

2

1.68

0.3420

NUAK1,PLCB1

Striatum

Early Fetal

3.04E-40

441

12

1.13

0.3805

CHD1,PPM1D,TCF3,WHSC1,RFX7,ERI1,TTK,POLD1,DNMT3A,SM
ARCE1,ABL1,PBX1

Amygda
la
Hippoca
mpus
Thalam
us
Thalam

Middle Late
Childhood
Middle Late
Childhood
Young
Adulthood
Late Mid

1

21

1

2.02

0.4023

FERMT1

1

57

2

1.47

0.4028

NR3C2,NCKAP1

1

105

3

1.19

0.4687

SHANK3,TCF7L2,SCN1A

1

109

3

1.14

0.4934

TGM1,WNT9A,TCF7L2

Cortex
Cortex
Cerebell
um
Thalam
us
Cerebell
um
Cerebell
um

Late Mid
Fetal
Middle Late
Childhood
Neotal Early
Infancy
Early
Childhood
Late Mid
Fetal
Early Mid
Fetal
Young
Adulthood
Adolescence
Young
Adulthood
Early Mid
Fetal
Early
Childhood
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us
Thalam
us
Hippoca
mpus
Thalam
us
Striatum
Cerebell
um
Cortex
Cortex
Hippoca
mpus
Hippoca
mpus
Thalam
us
Hippoca
mpus
Striatum
Thalam
us
Amygda
la
Hippoca
mpus
Striatum
Striatum
Striatum

Fetal
Adolescence

1

113

3

1.10

0.5175

ACHE,TCF7L2,SCN1A

1

73

2

1.14

0.5304

NR3C2,MYO1E

1

116

3

1.07

0.5351

FERMT1,TCF7L2,SCN1A

7.64E-06

208

5

0.99

0.5685

TTK,POLD1,FERMT1,FOXP1,KDM6B

1

122

3

1.02

0.5694

PTK7,RELN,ATP1A1

1

91

2

0.91

0.6502

JUP,TBR1

1

43

1

0.96

0.6516

GRIN2B

Adolescence

1

94

2

0.88

0.6677

NR3C2,SHANK3

Late Fetal

1

105

2

0.78

0.7256

PLVAP,TTK

Late Fetal

1

114

2

0.72

0.7665

ACHE,TCF7L2

1

60

1

0.68

0.7706

WNT7B

1

61

1

0.67

0.7761

PLCB1

Late Infancy

1

62

1

0.66

0.7816

TCF7L2

Late Fetal

1

119

2

0.69

0.7868

TBR1,ERI1

1

64

1

0.64

0.7920

NR3C2

1

72

1

0.57

0.8292

FERMT1

1

86

1

0.47

0.8790

RPL12

1

107

1

0.38

0.9278

MYO1E

Early
Childhood
Middle Late
Childhood
Late Fetal
Neotal Early
Infancy
Late Fetal
Early
Childhood

Neotal Early
Infancy
Early
Childhood

Young
Adulthood
Middle Late
Childhood
Late Infancy
Young
Adulthood
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Striatum
Amygda
la
Amygda
la
Hippoca
mpus
Amygda
la
Amygda
la
Amygda
la
Cortex

Adolescence
Neotal Early
Infancy
Early
Childhood

1

136

1

0.30

0.9647

1

41

0

0.00

1

1

29

0

0.00

1

Late Infancy

1

72

0

0.00

1

Adolescence

1

62

0

0.00

1

Late Infancy

1

77

0

0.00

1

Young
1
52
0
0.00
1
Adulthood
Late Infancy
1
41
0
0.00
1
Neotal Early
Striatum
1
95
0
0.00
1
Infancy
pASD, potential ASD genes (n=441); OR, odds ratio. P-values and odds ratios are from one-sided Fisher’s exact test s.
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PLCB1

Table 3.7 Co-expression modules in the brain.

Module

#Gene

Expression
pattern

Enrichment

#EG

Odds ratio
(EG/NEG)

#NEG

p-value
(EG/NEG)

#Potential
ASD genes

Odds ratio

p-value

(ASD genes)

(ASD genes)

M01

1601

Early expressed

EG-enriched

501

251

2.73

7.38*10-38

55

1.52

0.004

M02

1150

Early expressed

EG-enriched

367

208

2.34

2.80*10-22

53

2.13

2.58×10-6

M03

1054

Mixed

NEG-enriched

204

340

0.74

9.67*10-4

18

0.72

0.934

M04

810

Late expressed

NEG-enriched

122

326

0.45

3.19*10-14

19

1.00

0.529

M05

781

Late expressed

NEG-enriched

156

239

0.81

0.0491

24

1.32

0.122

M06

702

Late expressed

NEG-enriched

129

254

0.63

1.55*10-5

11

0.65

0.948

M07

663

Early expressed

EG-enriched

251

141

2.32

1.23*10-15

8

0.50

0.989

M08

580

Early expressed

EG-enriched

193

114

2.19

3.62*10-11

13

0.95

0.613

M09

559

Late expressed

NEG-enriched

104

206

0.62

9.26*10-5

16

1.23

0.246

M10

503

Early expressed

EG-enriched

126

114

1.40

0.0102

9

0.74

0.847

M11

457

Late expressed

NEG-enriched

79

178

0.55

7.33*10-6

9

0.83

0.753

M12

420

Late expressed

NEG-enriched

62

163

0.47

1.90*10-7

7

0.69

0.874

M13

418

Late expressed

NEG-enriched

97

193

0.62

1.46*10-4

7

0.69

0.877

M14

370

Late expressed

EG-enriched

81

58

1.77

0.00102

4

0.45

0.977

93

M15

368

Mixed

EG-enriched

104

95

1.39

0.0251

5

0.57

0.934

M16

347

Early expressed

EG-enriched

106

90

1.49

0.00570

20

2.57

2.80×10-4

M17

339

Early expressed

EG-enriched

102

59

2.20

1.20*10-06

16

2.05

0.008

M18

306

Late expressed

66

61

1.37

0.0874

5

0.67

0.861

M19

299

Late expressed

NEG-enriched

31

118

0.32

1.81*10-9

2

0.28

0.994

M20

296

Late expressed

NEG-enriched

51

91

0.70

0.0498

5

0.72

0.823

M21

291

Early expressed

54

73

0.93

0.719

5

0.72

0.818

M22

278

Early expressed

EG-enriched

83

25

4.24

6.17*10-12

2

0.29

0.991

M23

272

Late expressed

NEG-enriched

41

84

0.61

0.0108

2

0.31

0.988

M24

258

Early expressed

51

49

1.31

0.189

11

1.84

0.047

M25

244

Early expressed

EG-enriched

86

49

2.23

6.66*10-6

11

1.98

0.031

M26

239

Early expressed

EG-enriched

79

18

5.61

8.28*10-14

4

0.70

0.821

M27

213

Late expressed

NEG-enriched

45

85

0.66

0.0261

6

1.19

0.399

M28

197

Late expressed

32

41

0.98

1

1

0.21

0.991

M29

193

Late expressed

NEG-enriched

33

69

0.60

0.0158

2

0.43

0.943

M30

188

Late expressed

NEG-enriched

11

43

0.32

2.92*10-4

3

0.69

0.808

M31

187

Late expressed

41

64

0.80

0.323

6

1.38

0.279

M32

172

Late expressed

24

60

0.50

0.00388

3

0.75

0.766

NEG-enriched
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M33

170

Late expressed

M34

163

Mixed

M35

151

Mixed

M36

151

Late expressed

M37

146

Early expressed

M38

128

Late expressed

M39

115

Early expressed

M40

99

unknown

M41

74

unknown

41

40

1.29

0.263

4

1.00

0.568

EG-enriched

48

22

2.76

5.06*10-5

2

0.51

0.904

NEG-enriched

21

48

0.55

0.0207

6

1.73

0.147

22

44

0.63

0.0815

3

0.82

0.707

EG-enriched

38

9

5.35

3.81*10-7

2

0.57

0.862

NEG-enriched

17

63

0.34

2.11*10-5

4

1.36

0.347

29

42

0.87

0.632

4

1.47

0.298

4

13

0.39

0.0926

1

0.45

0.890

4

16

0.31

0.0400

1

0.59

0.816

NEG-enriched

P-values with statistical significance are in bold.
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Table 3.8 Reactome pathways enriched in three EG-enriched modules implicated in ASD.

Module

M01

Term

Overlap

p-value

Adjusted p-value

Transcription

25/202

2.40*10-6

6.79*10-4

Processing of Capped IntronContaining Pre-mRNA

22/144

4.34*10-7

3.67*10-4

Folding of actin by CCT/TriC

7/9

1.11*10-6

4.70*10-4

mRNA Splicing

17/113

1.11*10-5

0.00188

HIV Infection

23/218

6.34*10-5

0.00589

HIV Life Cycle

18/137

3.19*10-5

0.00451

snRNP Assembly

10/49

8.30*10-5

0.00589

7/20

5.94*10-5

0.00589

CCT3;CCT6A;CCT2;TCP1;CCT7;CCT5;CCT4

8/29

7.19*10-5

0.00589

CCT3;CCT6A;CCT2;TCP1;XRN2;CCT7;CCT5;CCT4

10/53

1.47*10-4

0.00890

SQLE;SEC24B;GGPS1;NFYA;TGS1;CYP51A1;HMGCR;
SEC24D;KPNB1;FDFT1

Formation of tubulin folding
intermediates by CCT/TriC
Association of TriC/CCT with target
proteins during biosynthesis
Regulation of cholesterol biosynthesis
by SREBP (SREBF)
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Genes
GTF3C3;HDAC2;CCNT2;GTF3C4;RRN3;CSTF3;GTF2E
1;CLP1;PCF11;POLR2B;SNAPC3;CSTF1;RNGTT;TBP;
NCBP1;NCBP2;GTF2H3;NFIA;POLR3B;NFIB;POLR3C;
POLR1B;POLR1E;TFAM;TAF5
NCBP1;NUP133;DHX9;NCBP2;CSTF3;CDC5L;HNRNP
U;PLRG1;YBX1;NUP160;EFTUD2;PRPF4;CLP1;HNRN
PH1;PCF11;POLR2B;NUP50;CSTF1;NUPL1;RAE1;SF3
B1;CTNNBL1
CCT3;CCT6A;CCT2;TCP1;CCT7;CCT5;CCT4
NCBP1;DHX9;NCBP2;CSTF3;CDC5L;HNRNPU;PLRG1
;YBX1;EFTUD2;PRPF4;CLP1;HNRNPH1;PCF11;POLR
2B;CSTF1;SF3B1;CTNNBL1
CCNT2;PSMD11;RNGTT;TBP;TSG101;NCBP1;NUP133
;NCBP2;XRCC5;HMGA1;NEDD4L;GTF2H3;GTF2E1;N
UP160;AP1G1;POLR2B;NUP50;PSMD2;TAF5;NUPL1;
PAK2;RAE1;KPNB1
CCNT2;RNGTT;TBP;TSG101;NCBP1;NUP133;NCBP2;
XRCC5;HMGA1;NEDD4L;GTF2H3;GTF2E1;NUP160;P
OLR2B;NUP50;TAF5;NUPL1;RAE1
NCBP1;NUP133;NCBP2;NUP50;TGS1;DDX20;NUPL1;
RAE1;NUP160;WDR77

M02

Chromatin organization

35/208

3.76*10-15

1.41*10-12

Processing of Capped IntronContaining Pre-mRNA

19/144

3.55*10-7

8.87*10-5

Transcription

18/202

1.02*10-4

0.00660

PKMTs methylate histone lysines
Transport of Mature mRNA derived
from an Intron-Containing Transcript

7/29

8.03*10-5

0.00660

9/50

5.80*10

-5

0.00660

HATs acetylate histones

13/105

4.91*10-5

0.00660

Transport of Mature Transcript to
Cytoplasm

9/54

9.84*10-5

0.00660

mRNA Splicing

13/113

9.74*10-5

0.00660

13/114

1.06*10-4

0.00660

11/78

6.57*10-5

0.00660

11/327

2.24*10-4

0.0740

3/13

3.84*10-4

0.0740

INPP4A;PIKFYVE;PIK3C3

3/27

2.54*10-3

0.122

PDPK1;BRAF;GRIN2B

5/92

0.00191

0.122

PDPK1;GRB10;PIK3C3;TSC1;MTOR

Regulation of lipid metabolism by
Peroxisome proliferator-activated
receptor alpha (PPARalpha)
Transcriptional regulation of white
adipocyte differentiation
Axon guidance
M16

PHF2;KDM5C;SMARCB1;TRRAP;EHMT2;EHMT1;CHD
4;ACTB;PHF21A;NSD1;SAP130;EP400;WDR5;EP300;B
RD8;WHSC1;MTA2;KDM6B;BRD1;CREBBP;KDM4B;S
MARCC2;KDM2B;SETDB1;SETD1B;USP22;D
NMT3A;ARID1A;GATAD2A;HCFC1;SMARCA4;NCOR1;
KAT6B;KAT6A;RCOR1
NUP214;SF3A1;SF3B2;SF3B3;NUP155;FUS;DDX23;SM
C1A;PRPF8;SRRM1;NUP93;PRPF6;U2AF2;NUP62;PO
LR2D;TPR;DHX38;NUP98;SNRNP200
GTF3C1;NFIX;POU2F1;EHMT2;CHD4;SSRP1;GATAD2
A;SRRM1;POLR3A;POLR1A;U2AF2;POLR2D;TCEB3;U
BTF;DHX38;MTA2;TAF4;TAF1
SETDB1;EHMT2;NSD1;SETD1B;WDR5;EHMT1;WHSC1
NUP214;NUP93;NUP155;U2AF2;NUP62;TPR;DHX38;N
UP98;SRRM1
BRD1;CREBBP;TRRAP;USP22;ACTB;HCFC1;KAT6B;K
AT6A;SAP130;EP400;WDR5;EP300;BRD8
NUP214;NUP93;NUP155;U2AF2;NUP62;TPR;DHX38;N
UP98;SRRM1
SF3A1;SF3B2;SF3B3;FUS;DDX23;SMC1A;PRPF8;SRR
M1;PRPF6;U2AF2;POLR2D;DHX38;SNRNP200

Synthesis of PIPs at the early endosome
membrane
CREB phosphorylation through the
activation of Ras
Insulin receptor signalling cascade
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ABCA1;MED1;CREBBP;NCOA6;NRF1;MED26;SREBF2
;MED12;MED14;MED24;NCOR1;SIN3A;EP300
MED12;MED1;CREBBP;MED14;MED24;NCOR1;NCOA
6;EP300;LPL;MED26;SREBF2
GSK3B;ARHGEF12;ROCK2;RASA1;KCNQ3;ANK2;ANK
3;ARHGEF7;GRIN2B;MYH10;ITGA9

EPH-Ephrin signaling
Sema4D induced cell migration and
growth-cone collapse
Interaction between L1 and Ankyrins

5/94

0.00209

0.122

ROCK2;RASA1;ARHGEF7;GRIN2B;MYH10

3/24

0.00187

0.122

ARHGEF12;ROCK2;MYH10

3/29

0.00306

0.131

KCNQ3;ANK2;ANK3

Post NMDA receptor activation events

3/35

0.00501

0.143

PDPK1;BRAF;GRIN2B

Signaling by Insulin receptor

5/116

0.00497

0.143

PDPK1;GRB10;PIK3C3;TSC1;MTOR

PI3K Cascade
4/68
0.00423
0.143
PDPK1;PIK3C3;TSC1;MTOR
CREB, cAMP response element binding protein; HATs, histone acetyltransferases; NMDA, N-methyl-D-aspartate; PKMTs, protein lysine methyltransferases;
PIPs, phosphatidylinositol phosphates; PI3K, phosphoinositide 3-kinase; snRNP, small nuclear ribonucleo proteins; SREBP, sterol regulatory element-binding
proteins; TriC/CCT, TCP1-ring complex or chaperonin containing TCP1. Adjusted P-values with statistical significance are in bold.

98

Table 3.9 Priority list of 29 essential genes as strong ASD candidates.

M02

TADA
FDR qvalue
0.47

# High-confidence
ASD genes that
are co-expressed
15

98928957

M01

0.17

15

CHD8 has been previously associated with autism

148697914

148801036

M01

0.49

12

-

5

55256245

55307722

M01

0.40

17

-

DVL3

3

184155388

184173610

M02

0.33

10

Robinow syndrome-3, characterized by skeletal abnormalities

EP300

22

41091786

41180077

M02

0.45

13

EP400

12

131949920

132081102

M02

0.43

9

Gene

Chr

Start

End

Module

BIRC6

2

32357028

32618899

CHD1

5

98853985

CUL1

7

DHX29

Disease associations
-

Rubinstein-Taybi syndrome, characterized by short stature,
moderate to severe learning difficulties, distinctive facial
features, and broad thumbs and first toes.
-

FBXO11

2

47789316

47905793

M01

0.15

17

KDM4B

19

4969113

5153595

M02

0.30

14

Associated with chronic otitis media with effusion and
recurrent otitis media, a hearing loss disorder, and the ENU
knockout of the homologous mouse gene results in the deaf
mouse mutant Jeff (Jf)
-

LDB1

10

102107560

102120453

M02

0.42

14

-

LTN1

21

28928144

28992956

M16

0.37

3

-

MORC3

21

36320189

36386148

M01

0.50

10

-

MYH10

17

NFIB

9

PBX1

1

8630761

M16

0.13

3

14081843

14398983

M01

0.45

15

Essential for normal spine morphology and dynamics.
Pharmacologic or genetic inhibition of Myh10 altered
protrusive motility of spines, destabilized their mushroomhead morphology, and impaired excitatory synaptic
transmission.
-

164555584

164899296

M01

0.46

16

-

8474205
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PHF21A

11

45929323

46121178

M02

0.48

11

-

RFX7

15

56087280

56243266

M01

0.25

17

-

RNF38

9

36336396

36487548

M01

0.41

18

-

SMARCE1

17

40624962

40648508

M01

0.41

12

Meningiomas (brain and spinal cord tumors)

SNW1

14

77717599

77761207

M01

0.44

12

-

STXBP5

6

147204425

147390476

M16

0.37

2

-

SUFU

10

102503987

102633535

M02

0.47

14

Familial Meningioma, Medulloblastoma

TAF4

20

61953469

62065810

M02

0.30

10

TANC2

17

63009556

63427699

M02

0.32

14

Interference of transcription by the binding of TAF4 with
expanded polyQ stretches is involved in the pathogenetic
mechanisms underlying neurodegeneration.
-

TNPO3

7

128954180

129055173

M01

0.19

17

Mutations found in patients with muscular dystrophy

UTP6

17

31860899

31901765

M01

0.19

12

-

VCP

9

35056064

35073249

M02

0.49

9

WHSC1

4

1871424

1982207

M02

0.27

13

YTHDC1

4

68310387

68350089

M01

0.48

11

100

Inclusion Body Myopathy with Paget Disease of Bone and
Frontotemporal Dementia, Amyotrophic Lateral Sclerosis,
Charcot-Marie-Tooth Disease Type 2Y
Located in the Wolf-Hirschhorn syndrome (WHS) critical
region
-

Supplementary data
Supplementary data 3.1 List of de novo variants in EGs and NEGs in subjects from
the Simons Simplex Collection.
Supplementary data 3.2 List of inherited variants in EGs and NEGs in subjects
from the Simons Simplex Collection.
Supplementary data 3.3 Individual mutational burden, essentiality burden score,
polygenic risk score and rare deletion burden of subjects from the Simons Simplex
Collection.
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CHAPTER 4: Essentiality burden score and its application to
understanding the genetic architecture of ASD
Introduction
A current model for understanding the genetic etiology of ASD involves the cumulative
effects of both common and rare variants including both SNVs and CNVs (de la TorreUbieta et al., 2016). A few polygenic methods for investigating the genetic architecture of
complex disorders have been proposed (Wray et al., 2014). Polygenic risk score (PRS)
aims to provide insight into the genetic architecture captured by common SNVs from
GWAS (International Schizophrenia et al., 2009). Specifically, PRS for each individual is
calculated as the number of risk alleles weighted by their effect sizes estimated from a
discovery GWAS (Wray et al., 2014). Since PRS summarizes the individual-level genetic
effects among a group of SNVs that do not individually reach genome-wide significance,
it can be used to construct disease risk prediction models (Dudbridge, 2013). PRS
analyses have been applied in a few recent ASD studies. For example, The Autism
Genome Project Consortium performed a two-stage GWAS in a total of 2,705 ASD
familes (including 1,404 families in Stage 1 and 1,301 families in Stage 2) (Anney et al.,
2012; Anney et al., 2010). Anney et al. found that PRS based on summary statistics from
Stage 1 GWAS is a significant predictor of Stage 2 case-control status (Anney et al.,
2012), which validated the collective contribution of common variants to ASD risk.
Furthermore, based on ASD GWAS on ~5,000 cases and ~5,000 controls performed by
Psychiatric Genomics Consortium (Smoller et al., 2013), Weiner et al. compared the
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PRS between ~6,400 ASD children and their parents and confirmed that common
polygenic variants contribute to ASD risk in addition to strong acting de novo events
(Weiner et al., 2016). Recent studies on CNVs implicated their significant role in the
genetic architecture of ASD (Bucan et al., 2009; Glessner et al., 2009; Griswold et al.,
2012; Itsara et al., 2010; Levy et al., 2011; Malhotra and Sebat, 2012; Marshall et al.,
2008; Pinto et al., 2010b; Sanders et al., 2011; Sanders et al., 2015; Sebat et al., 2007;
Szatmari et al., 2007). Global CNV load, which is defined as the total number of base
pairs covered by CNVs per individual, had been suggested to predispose to autism
(Girirajan et al., 2013). While PRS captures the cumulative effect of common variants in
both EGs and NEGs, based on an increased burden of inherited, rare and damaging
mutations in EGs in ASD probands compared to their unaffected siblings (Ji et al., 2016),
I suggested that the burden of rare variants in EGs could be an additional polygenic
predictor of individual ASD risk.
In the previous chapter, I defined the individual mutation burden as i) the number of
alternative alleles below a defined threshold of minor allele frequency (MAF<0.01) and
ii) above a defined threshold of the Combined Annotation-Dependent Depletion (CADD)
score that measures variant-level deleteriousness by integrating diverse genome
annotations (CADD phred-scale>10) (Ji et al., 2016). However, the individual mutation
burden did not take into account the magnitude of damaging effects for each variant, and
thus may not be an optimal predictor of individual ASD risk. To evaluate the optimal
predictor of individual’s ASD risk and to improve the power to differentiate unaffected
individuals from ASD subjects with different degrees of social and cognitive impairment,
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I developed an Essentiality Burden Score (EBS). The EBS is defined as the weighted sum
of coding variants in essential genes per individual. The weights are based on measures
of variant-level deleteriousness (as a proxy for pathogenicity), minor allele frequency
(MAF), and gene-level intolerance scores (Aggarwala and Voight, 2016; Lek et al., 2016;
Petrovski et al., 2013) . The optimized weighing scheme for EBS can be found by
maximizing the difference in EBS between ASD patients and unaffected siblings in the
discovery dataset (1,781 ASD proband-siblings pairs from Simons Simplex Collection,
Table 4.1).
Using weights learned in the discovery phase, I calculated EBS for individuals and
families in the target dataset (688 trio families in the ASC exome sequencing dataset,
Table 4.1) for validation of the association of EBS to ASD using parent-child
relationships. To demonstrate how EBS can facilitate a deeper understanding of the
genetic architecture of ASD, I compared EBS, PRS and CNV load and evaluate the
power of these polygenic methods in predicting ASD disease status. Moreover, I
investigated the potential interplay between EBS and rare variants in high-penetrant ASD
risk genes such as NRXN1.
Results
Optimization of the essentiality burden score (EBS)
I evaluated the performance of EBS under different weighing schemes in the discovery
sample (1,781 ASD proband-sibling pairs from SSC). The contributions of CADD score,
MAF [non-Finnish European population in ExAc, (Lek et al., 2016)] and intolerance
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scores for the performance of EBS were assessed by four metrics: P values and effect
sizes from one-sided Wilcoxon signed rank test for higher EBS in ASD probands;
percentage of proband-sibling pairs in which probands have higher EBS (accuracy); area
under ROC curve (AUC) for the performance of EBS in discriminating between ASD
probands and unaffected siblings (Figure 4.2). I observed that both intolerance scores and
CADD score contribute to improved performance of EBS, and that MAF contribute
minimally to the performance of EBS. The product of the weights from CADD scores
and intolerance scores provides the best performance for EBS (Figure 4.2, Table 4.3,
Materials and Methods). Under this model, the P value for elevated EBS in 1,781 ASD
probands compared to their unaffected siblings is 2.26 ×10-5, which is a substantial
improvement compared with the individual mutational burden described in chapter 3 (P
value =0.0021) (Ji et al., 2016). It is notable that although the effect of increased EBS in
ASD probands is statistically significant, the predicting power of EBS in differentiating
between ASD probands and unaffected siblings is modest (accuracy=0.542,
AUC=0.520).
Regression analysis of the effect of EBS on quantitative traits of ASD probands
Next I investigated the relationship between EBS and quantitative traits available for
~2,500 ASD probands in SSC (Supplementary data 3.3). I confirmed the significant
effect of EBS on Social Responsiveness Scale (SRS) in male probands (P value=2.32
×10-6; Poisson regression) but not in female probands (P value =0.085; Poisson
regression), as well as the effect of EBS on verbal and non-verbal IQ (P value <2 ×10-16
for both verbal and non-verbal IQ; Poisson regression). Moreover, increased EBS in
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probands is associated with parents’ age at their births, with a stronger effect on the age
of fathers (P value =0.00414; Poisson regression) than mothers (P value =0.0109; Poisson
regression). When EBS was dissected by the contributions of de novo or inherited
mutations separately, both de novo and inherited mutations contribute to this effect on the
age of fathers (P value =1.11 ×10-8 for de novo, P value = 0.0384 for inherited; Poisson
regression) and mothers (P value = 0.00849 for de novo, P value = 0.0283 for inherited;
Poisson regression). EBS in the probands is not associated with probands’ head
circumference (P value = 0.695; Poisson regression) and number of miscarriages in the
family (P value = 0.40; Poisson regression).
The extension of polygenic transmission disequilibrium test to EBS
It is expected that a child inherits half of the variants from each of their parents, thus the
child’s expected EBS is the average EBS of their parents. However, in a collection of trio
families in which the children are affected with a trait or disease (such as ASD), the
association between EBS and the trait introduces deviation of children’s EBS from the
expected value. To further validate the association of EBS to ASD using parent-child
relationships in the ASC exome sequencing dataset, I extended the polygenic
transmission disequilibrium test (Weiner et al., 2016) to EBS. The extension of the
transmission disequilibrium test to EBS is equivalent to testing the difference between
affected children’s EBS and the means of paternal and maternal EBS. Using exome
sequencing data of 688 ASD trio families from Autism Sequencing Collaboration, I
compared the EBS of ASD children with their unaffected parents (Figure 4.3,
Supplementary data 4.1). I found that the EBS of ASD children were greater than the
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paternal EBS (P value =0.0136; paired two-sample t-test, one-sided), but not the maternal
EBS (P value = 0.6632; paired two-sample t-test, one-sided). In addition, the maternal
EBS were marginally greater than paternal EBS in these families (P value = 0.0524;
paired two-sample t-test, one-sided). I did not detect significantly increased EBS of ASD
children compared to both parents (P value = 0.3675; one-sided two-sample t-test). I
found that the ASD children’s EBS is marginally increased compared to the means of
paternal and maternal EBS (P value = 0.054, paired two-sample t-test, one-sided), further
supporting the association between increased burden of deleterious variants in EGs and
ASD.
The independent contributions of EBS, polygenic risk score (PRS) and rare deletion
burden (RDB) for ASD risk prediction
The cumulative effect of rare variants in EGs is not the only factor that determines ASD
disease status, as polygenic effect of common variants, burden of copy number variations
(CNVs) and rare variants with high penetrance can be additional genetic factors that
predict ASD risk. To test this hypothesis, I took advantage of available exome
sequencing and SNP genotyping data of 701 SSC families for which both EBS and PRS
could be estimated. The EBS of the 701 SSC proband-sibling pairs were calculated using
called variants in their exomes. Using the SNP genotyping data of 701 SSC probandsibling pairs, I calculated their PRS based on the summary statistics in a GWAS on 5,305
ASD cases and 5,305 psuedocontrols performed by the Psychiatry Genomics Consortium
(Smoller et al., 2013). A low negative correlation was observed between the EBS and
PRS of 701 SSC ASD probands (Pearson correlation = -0.318, Figure 4.4), suggesting
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that the effects of EBS and PRS were independent to each other. Based on a list of rare
CNVs in ~2,500 SSC ASD families (Table 4.2) (Sanders et al., 2015), I calculated the
rare deletion burden (RDB) of these individuals. RDB was not correlated with either EBS
(Pearson correlation=0.042) or PRS (Pearson correlation=-0.056). To evaluate and
compare the performance of EBS, PRS and RDB in predicting ASD affected status, I
performed logistic regression using the EBS, PRS and RDB of 670 proband-sibling pairs
as independent variables. The performance of regression models based combinations of
the three metrics considered (EBS, PRS, and RDB) was evaluated by area under ROC
curve (AUC) (Figure 4.5). The performance of EBS and that of RDB alone was modest
(EBS: AUC=0.514; RDB: AUC=0.515). The performance of PRS is inflated (PRS:
AUC=0.806), probably because the ASD GWAS from PGC included overlapping
subjects from the SSC cohorts. Regardless of the inflated performance of PRS, EBS and
RDB still improved the prediction power when incorporated together with PRS
(EBS+PRS: AUC=0.831; RDB+PRS: AUC=0.811). The best performance was achieved
when the regression model included all of the three metrics (EBS+RDB+PRS:
AUC=0.833) (Figure 4.5, Table 4.4). The regression coefficients of PRS, EBS and RDB
were all significant (PRS: P value <2 ×10-16; EBS: P value =1.28 ×10-12; RDB: P value
=0.0131). The effect of EBS on ASD affected status was stronger than that of RDB
(EBS: coefficient=0.518; RDB: coefficient=0.333). Overall, the results suggest that EBS,
PRS and RDB capture different aspects of the genomic landscape of ASD and provide
more power to predict ASD risk when combined and considered together.
The interplay between EBS and NRXN1 variants with a major effect
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Next I hypothesized that high-penetrant alleles in ASD risk genes may play an important
role in some ASD individuals with lower EBS. NRXN1 is a synaptic cell-adhesion
molecule and a component of the trans-synaptic complex, which is crucial for normal
synapse formation and function. NRXN1 is also an unpublished EG (personal
communication with Mark V. Fuccillo) that is significantly associated with ASD [TADA
FDR=2.31 ×10-7, (Sanders et al., 2015)]. To investigate the potential interplay between
rare variants in NRXN1 and EBS, I compiled a list of SSC families with rare CNVs and
SNVs in NRXN1 (Figure 4.6). Firstly, I extracted 7 ASD families from SSC with rare
exonic deletions in NRXN1 in at least one child, among which 6 are quartet families
(Table 4.5). All of these 6 rare exonic deletions in NRXN1 were in probands (4 inherited
and 2 de novo) and none was present in siblings only, indicating that these deletions
could have strong effects and lead to ASD. Among the 7 probands with rare exonic
deletions in NRXN1, 5 had lower EBS compared to their unaffected siblings. Secondly, I
extracted 19 ASD quartet families from 1,781 SSC families in which rare functional
mutations in NRXN1 were present in at least one child (Figure 4.6, Table 4.6). There were
14 unique heterozygous mutations in NRXN1 in these 19 families (13 inherited and 1 de
novo). With the assumption that NRXN1 mutations present in probands have stronger
penetrance than those mutations only observed in unaffected siblings, I found that ASD
probands with high-penetrance NRXN1 mutations are more likely to have lower EBS
compared to their siblings (odds ratio=11.25, P value=0.0495; one-sided Fisher’s exact
test) (Table 4.7). These findings suggest that in some ASD patients, alleles in highpenetrance ASD risk genes such as NRXN1 play an important role in the development of
ASD, regardless of their lower mutational burden in EGs.
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Discussion
I developed the essentiality burden score (EBS) by giving weights to different variants
according to their functional impact, which provides greater power to separate ASD
probands from their unaffected siblings. I validated the effectiveness of EBS in an
independent cohort (ASC) by extending the polygenic transmission disequilibrium test to
EBS and showed that the EBS of ASD probands tends to be higher than the average EBS
of their parents. I demonstrated the independent contributions of EBS, polygenic risk
score (PRS) and rare deletion burden (RDB) for ASD risk prediction. Finally, I observed
a potential interplay between EBS and NRXN1 variants with a major effect in ASD
probands from Simons Simplex Collection.
Since the era of genome-wide association studies (GWAS), the large proportion of the
heritability of complex disorders such as ASD unexplained by GWAS, i.e. the “missing
heritability” (Manolio et al., 2009; McCarthy et al., 2008), remains as a key question to
be answered. With the advancement of next generation sequencing technology, many
recent ASD studies have been successful in identifying many more ASD candidate genes
by focusing on rare and de novo variants with a large functional impact (Iossifov et al.,
2014; Iossifov et al., 2012; Levy et al., 2011; Sanders et al., 2011; Sanders et al., 2012).
Besides common variants in GWAS or rare variants with large genetic effect, my study
focused on an important but less explored territory: low-frequency or rare variants with
small to intermediate effect in EGs (Figure 4.7). The EBS captures the cumulative effect
of a large number of rare deleterious variants in EGs. I found significantly elevated EBS
in ASD probands and an independent contribution of EBS to ASD risk prediction, which
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suggests that EBS analysis, along with PRS analysis that captures cumulative effect of
common variants, is useful in identifying the “still-missing” heritability of ASD and thus
important for a full understanding of the genetic landscape of ASD. Moreover, my results
on elevated EBS in unaffected mothers compared to unaffected fathers in ASD trio
families from the ASC cohort further support the “female protective model” in ASD, for
which several studies have gathered reinforcing genetic evidence showing a higher
burden of de novo loss-of function mutations (Iossifov et al., 2012) and CNVs
(Jacquemont et al., 2014; Levy et al., 2011; Sanders et al., 2011; Sanders et al., 2015) in
female ASD probands.
It is not surprising that the predictive power of EBS alone on ASD risk is only moderate.
Firstly, due to the complexity of the genomic architecture of ASD (de la Torre-Ubieta et
al., 2016), we may expect that it is not a single genetic predictor but the joint contribution
of a broad spectrum of genetic variants (Figure 4.7) that determines the genetic risk of
ASD. This notion is supported by my results that i) the performance of ASD predicting
models including all three genetic predictors (i.e. EBS, PRS and RDB) is superior to the
models with only a single predictor and ii) high-penetrant NRXN1 mutations are
associated with lower EBS in ASD probands. Secondly, for complex genetic disorders we
may expect an influence of environmental factors, and therefore the predictive value of a
single genetic risk factor is limited (Wray et al., 2014; Wray et al., 2010). Other identified
non-genetic factors in ASD such as parental age, prenatal stress or infection, maternal
Zn2+-deficiency and maternal exposure of toxins (Grabrucker, 2012), should also be
taken into consideration in order to increase the predictive ability of genetic predictors
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(Wray et al., 2014). Thirdly, there are still limitations in the current model for EBS,
which has not taken into consideration variants in the X chromosome (that harbors 89
EGs) and non-coding variants involved in regulating the expression of EGs. Finally, it is
expected that EBS will achieve a better predictive value for ASD risk as the catalog of
EGs continues to grow.
Materials and Methods
ASC exome sequencing data
Exome sequence reads of 3,417 individuals in ARRA Autism Sequencing Collaboration
(ASC) were downloaded from dbGaP (https://www.ncbi.nlm.nih.gov/gap; dbGaP Study
Accession: phs000298.v1.p1). The reads were aligned to GRCh37/hg19 human genome
with Burrows-Wheeler Aligner (BWA) 0.7.10 (Li and Durbin, 2009). Variant calling was
performed with the Genome Analysis Toolkit (GATK) (3.2.2) with default protocols
(McKenna et al., 2010). Variant filters include i) passed the GATK variant quality score
recalibration (VQSR) filter, ii) call rate>=90% and c) Hardy Weinberg equilibrium P
value >1× 10-6. Genotype filters include i) read depth (DP) >=8 and ii) genotype quality
(GQ) >=20. The final variant call set included 934,511 variants with an average call rate
of 99.2% and a transition / transversion ratio of 2.75. From the 3,417 individuals, I
extracted 688 trio families with two unaffected parents and a child affected with ASD.
SSC SNP genotyping data
I obtained Illumina 1M SNP genotyping data of 4,753 individuals (1,223 probands and
3,530 unaffected family members) in SSC. Invariant markers, duplicated variants, non112

autosomal variants and variants with call rate <90% and Hardy Weinberg equilibrium P
value < 1×10-7 were removed. The final variant call set included 886,001 variants with
an average call rate of 99.96%. The chromosomal positions of the variants were lifted
over from hg18 to hg19 using the LiftOver tool from UCSC genome browser
(https://genome.ucsc.edu). SNP array data were available for 701 SSC proband-sibling
pairs among the 1,781 quartet families with exome sequencing data.
Definition and optimization of the essentiality burden score (EBS)
To calculate the EBS, suppose there are n functional variants (loss-of-function or
missense) in a whole exome sequence or whole genome sequence dataset, Iij indicates
whether variant j exists in individual i. The EBS for individual i is defined as the
weighted sum of the number of risk alleles in an individual:
𝑛

𝐸𝐸𝐸𝑖 = ��𝑊𝑗 𝐼𝑖𝑖 �
𝑗=1

For each functional variant, the weighing metric (W) combines evidence from i) minor
allele frequency (MAF) in ExAC (European ancestry) (Lek et al., 2016), ii) variant-level
deleteriousness quantified by CADD score (Kircher et al., 2014) and iii) gene-level
intolerance scores including Residual Variation Intolerance Score (RVIS) (Petrovski et
al., 2013), the probability of being loss-of-function intolerant (pLI) (Dickinson et al.,
2016)and genic intolerance based on sequence context (Aggarwala’s score) (Aggarwala
and Voight, 2016) .
WCADD = CADD phred-scale score
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WMAF = [Beta (MAF; 1,25)] 2 (Wu et al., 2011)
Wintolerance =100-(RVIS percentile+pLI percentile+Aggarwala percentile)/3
W= (WCADD*a1+ WMAF*a2)*Wintolerance^a3
The objective of optimization was to learn the weights (a1, a2 and a3), using the discovery
dataset, that maximally differentiates ASD cases from family controls. To achieve this, I
used annotated variants in the discovery sample [1,781 ASD quartet families from SSC,
specifically, variants reported in (Iossifov et al., 2014) and (Krumm et al., 2015)], to
identify a combination of weighing metrics by maximizing the performance of EBS in
differentiating between ASD probands and unaffected siblings. The performance of EBS
were assessed by four metrics: P values and effect sizes from one-sided Wilcoxon signed
rank test for higher EBS in ASD probands; percentage of proband-sibling pairs in which
probands have higher EBS (accuracy); area under ROC curve (AUC) for the performance
of EBS in discriminating between ASD probands and unaffected siblings.
Calculation of ASD polygenic risk score (PRS)
I downloaded GWAS results of a meta-analysis of 5,305 ASD-diagnosed cases and 5,305
psuedocontrols constructed from untransmitted parental chromosome performed by the
Psychiatric Genomics Consortium (Robinson et al., 2016). Using PRSice 1.25 (Euesden
et al., 2015), I calculated the PRS of 701 SSC proband-sibling pairs at a P value threshold
of 0.5, at which 1,223 probands were maximally differentiated from 3,530 unaffected
family members (Figure 4.1).
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Calculation of rare deletion burden (RDB)
I acquired a list of rare CNVs (with population frequency <= 0.1%) predicted from
Illumina Omni2.5 SNP genotyping data of 2,591 SSC ASD families (Table 4.2) (Sanders
et al., 2015). The rare deletion burden (RDB) was defined as the total number of base
pairs covered by rare deletions across an individual genome (Girirajan et al., 2013).
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Figures

Figure 4.1 PRS model fit across multiple GWAS P-value thresholds. The figure was
generated by PRSice 1.25. For each GWAS p-value threshold (x-axis), a regression was
performed to test the association between the PRS and ASD affected status of 1,223 SSC
probands and 3,530 unaffected family members. The R2 and p-value for each regression
model is shown.
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Figure 4.2 Optimization of parameters for EBS. Performance of EBS in the discovery
sample (1,781 ASD proband-sibling pairs from SSC) was evaluated with four metrics: (A)
p-values (B) effect sizes from one-sided Wilcoxon signed rank test for higher EBS in
ASD probands, (C) percentage of proband-sibling pairs in which probands have higher
EBS, (D) area under ROC curve for the performance of EBS in discriminating between
ASD probands and unaffected siblings.
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Figure 4.3 Essentiality burden scores in ASD trio families. The boxplots indicate the
distribution of essentiality burden score (EBS) of ASD children, mothers and fathers in
685 trio families from ARRA Autism Sequencing Collaboration. “Mean” stands for the
mean of paternal and maternal EBS. One-sided paired two-sample t-tests for increased
EBS in ASD children (top three p-values) and for increased EBS in mothers (bottom pvalue) were performed. *p-value<0.05.
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Figure 4.4 The EBS and PRS of 701 ASD probands. The Pearson correlation between
EBS and PRS is shown.

119

Figure 4.5 Performance of ASD prediction models. Multivariate logistic regression
was performed to predict the affected status of 670 proband-sibling pairs. Combinations
of three individual-level metrics [i.e. essentiality burden score (EBS), rare deletion
burden (RDB), and polygenic risk score (PRS)] were used as independent variables in the
regression models. The area under ROC curve for each of the six regression models is
shown.
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Figure 4.6 Rare exonic deletions and SNVs in NRXN1 in SSC. UCSC Genome
Browser (http://genome.ucsc.edu/) view of 7 families with rare exonic deletions (long red
bars) and 19 families with rare exonic SNVs (short red bars) in NRXN1 with SSC family
ID is shown.
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Figure 4.7 Spectrum of complex disease risk variants by allele frequency and effect
size. This figure is from ref (Manolio et al., 2009), which is adapted from ref (McCarthy
et al., 2008).
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Tables
Table 4.1 Datasets involved in Chapter 4.
Cohort

Sample size

Source

Illumina
HiSeq 2000

2,368 trio and
quartet families

Iossifov et al.
2014; Krumm et al.
2015

SNP genotyping

Illumina 1M

701 quartet
families

SSC

SSC

Rare CNVs

Illumina 1M
and Omni2.5

2,591 trio and
quartet families

Sanders et al. 2015

ASC

Whole exome
sequencing

Illumina
HiSeq 2000

688 trio
families

ASC (dbGaP)

SSC

SSC

Type
Rare variants (from
whole exome
sequencing)

Platform

The intersection between 2,369 families with rare variants and 2,591 families with rare
CNVs are 2,181. 701 families with SNP genotyping data are a subset of 2,368 families
with rare variants.
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Table 4.2 Statistics of rare CNVs in 2,591 SSC ASD families.
Deletion

Duplication

Exonic/Splicing

Intronic/UTR

Intergenic

Exonic/Splicing

Intronic/UTR

Intergenic

Both

173

15

184

504

0

65

EG

1379

1874

1271

1031

400

336

NEG

2144

2788

1611

1496

579

420

Unknown

8231

6518

10866

4747

1390

3226

Total

11927

11195

13932

7778

2369

4047
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Table 4.3 The performances of different models of essentiality burden score.
Model

P

Effect Size Accuracy

AUC

a1

a2

a3

Burden

0.0021

0.0901

0.5376

0.5126

.

.

.

MAF

0.0013

0.0884

0.5368

0.5129

0

1

0

CADD

0.0012

0.0889

0.5298

0.5139

10

0

0

MAF+CADD

0.0009

0.0906

0.5368

0.5129

10

1

0

Intol

7.15E-05

0.1088

0.5379

0.5198

.

.

.

MAF*Intol

7.41E-05

0.1086

0.5385

0.5198

0

1

1

CADD*Intol

4.52E-05

0.1118

0.5418

0.5196

10

0

1

(MAF+CADD)*Intol 5.31E-05

0.1108

0.5390

0.5187

10

1

1
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Table 4.4 Regression analysis to predict ASD affected status.
Estimate

Std. Error

Z value

p-value

EBS

0.51791

0.07298

7.096

1.28 ×10-12 *

RDB

0.33346

0.13444

2.480

0.0131 *

PRS

1.72517

0.09491

18.176

< 2 ×10-16 *

Intercept

0.08912

0.06945

1.283

0.199

Logistic regression was performed for the essentiality burden score (EBS), rare deletion
burden (RDB), and polygenic risk score (PRS) of 670 proband-sibling pairs from SSC. *
p-value <0.05.
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Table 4.5 ASD families from SSC with rare exonic deletions in NRXN1.
Family

Chr

Start

Stop

Inheritance

EBS proband

EBS sibling

EBS difference

12119

2

50831734

50873107

de novo

15598.29

NA

NA

12786

2

51158351

51661515

mother-both

24412.65

33687.31

-9274.67

13580

2

51247294

51311532

de novo

23413.55

18604.00

4809.55

13609

2

51236179

51332477

father-pro

459.63

1132.83

-673.20

13718

2

51087308

51161424

mother-pro

10865.98

17306.43

-6440.45

13962

2

50790714

51256013

de novo

8644.48

13599.03

-4954.55

14443

2

51149414

51255832

father-both

1798.76

1808.08

-9.32
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Table 4.6 ASD families from SSC with rare/damaging SNVs or indels in NRXN1.
Inheritance
mo-pro

EBS
proband
11078.04

EBS
sibling
19319.46

EBS
difference
-8241.42

Family

Chr

Start

Stop

Ref

Alt

13465

2

50280493

50280493

G

-

12115

2

50282085

50282085

-

T

fa-sib

8444.06

7978.35

465.71

12989

2

51253590

51253590

G

A

fa-both

18550.44

14013.83

4536.62

12501

2

50724605

50724605

A

T

de novo

14371.08

14798.24

-427.15

12032

2

50724817

50724817

G

A

mo-pro

23199.61

23704.83

-505.22

14241

2

50724817

50724817

G

A

fa-pro

18231.69

15067.18

3164.52

14629

2

50724817

50724817

G

A

fa-sib

15127.46

22051.87

-6924.41

12953

2

50724817

50724817

G

A

fa-pro

13878.68

16416.71

-2538.03

13852

2

50724817

50724817

G

A

mo-sib

729.02

0

729.02

13998

2

51255218

51255218

C

T

fa-both

36937.25

36923.27

13.98

13931

2

50149233

50149233

C

T

mo-pro

13900.33

16532.63

-2632.3

11030

2

50780151

50780151

T

A

mo-sib

13235.1

4629.40

8605.70

14523

2

50779938

50779938

G

T

mo-sib

24330.59

22213.44

2117.15

12484

2

50149314

50149314

G

A

mo-pro

19311.12

16490.36

2820.7

13944

2

50779784

50779784

A

C

mo-sib

27655.17

26322.5

1332.67

12950

2

50280477

50280477

T

A

mo-both

24713.45

27057.88

-2344.44

12695

2

50699532

50699532

G

C

mo-both

19295.37

23723.99

-4428.62

14225

2

51253608

51253608

C

T

fa-both

22945.78

24235.69

-1289.91

11721

2

51253608

51253608

C

T

fa-pro

21189.56

21563.92

-374.36

All listed variants have CADD score>10. mo, mother; fa, father.
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Table 4.7 Relationship between mutations in NRXN1 and EBS in ASD quartet
families.
NRXN1
mutation

Lower EBS in
probands

Higher EBS in
probands

Odds Ratio

p-value

in proband only

6

2

15

0.0513

in both

3

2

7.5

0.1970

in proband

9

4

11.25

0.0495 *

in sibling only

1

5

NA

NA

One-sided Fisher’s exact test was performed with “in sibling only” group as control. *pvalue <0.05.
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Supplementary data
Supplementary data 4.1 Essentiality burden score of subjects from the Autism
Sequencing Collection.
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CHAPTER 5: Conclusion and future directions
The goal of this dissertation is to systemically characterize human essential genes (EGs)
and investigate the role of EGs in neurodevelopmental disorders such as ASD. From the
analysis of the most comprehensive set of human EGs to date, this study demonstrated
that i) EGs are not only relevant but also important for both Mendelian and complex
diseases and ii) mutational load in EGs plays a significant role in the genetic basis of a
neurodevelopmental disorder, ASD. Therefore, the analysis of EGs can serve as an
important step for both interpretation and prioritization of ASD risk alleles, as well as a
full understanding of the genetic landscapes of ASD and possibly more complex diseases.
In light of the findings and discussions in previous chapters, I will discuss possible future
directions for the analysis of EGs.
Firstly, the extension of EG analysis to other complex diseases will further validate the
key findings in this dissertation and lead to new insights into the role of the
“essentialome” in human disease etiology. According to my results in Chapter 2, EGs are
especially enriched among genes associated with early onset diseases, which is consistent
with EGs’ vital role during embryonic development. Neurodevelopmental disorders (e.g.
ASD, intellectual disabilities, developmental co-ordination disorder and attentiondeficit/hyperactivity disorder) are a group of conditions that manifest early in the
development of children. Moreover, some neurodevelopmental disorders may share
similar genetic risk factors (Smoller et al., 2013) and they frequently co-occur (Leitner,
2014; Tonnsen et al., 2016). Therefore, neurodevelopmental disorders other than ASD
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are plausible targets for future analyses of EGs. However, we cannot rule out the
possibility that EGs could also play a role in later onset diseases, thus a comparison of the
contributions of EGs in early onset and late onset diseases is warranted.
Secondly, multiple lines of evidence suggest that genetic variants in functional elements
within noncoding genomic regions play an important role in complex diseases (Zhang
and Lupski, 2015). Since the coding regions of EGs are intolerant to deleterious
mutations, it is expected that the regulatory elements of EGs may also have a distinct
mutational spectrum. This notion is supported by Lek et al., who observed that the most
highly mutational constrained genes (which overlap greatly with EGs) are depleted for
expression quantitative loci (eQTL) (Lek et al., 2016). It implies that the regulatory
elements of EGs are less redundant and functional variants in these elements are more
likely to contribute to disease-related phenotypes. Therefore, a better understanding of
the regulatory elements of EGs will improve our ability to interpret the functional
consequences of non-coding variants discovered from whole genome sequencing studies.
Moreover, by including variants in noncoding regulatory regions of EGs in the individual
essentiality burden score (EBS), the power of EBS to predict individual ASD risk will
likely be enhanced. In order to achieve this goal, one of the key problems to be solved is
to credibly identify the regulatory elements for each EG. Multiple approaches can be
applied independently or together to identify the regulatory elements of EGs. For
example, analysis of eQTLs establishes the association between non-coding variants and
gene expression levels by combining whole genome sequencing data and RNA
sequencing data of the same individuals (Albert and Kruglyak, 2015). Chromosome
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conformation capture followed by massively parallel sequencing (Hi-C) allows whole
genome mapping of long range physical interactions (Lieberman-Aiden et al., 2009).
With careful data quality control and selection of predictive models, eQTL and/or Hi-C
data can be used to systematically assign regulatory elements to EGs.
Last but not least, compiling a complete set of ~6,000 putative human EGs will be an
achievable goal in the near future, as the genetic community including the International
Mouse Phenotyping Consortium (IMPC) continues to produce and phenotype knockout
mouse lines for the remainder of the ~20,000 genes in the mouse genome. Before this
task is completed, an alternative approach to expand the current catalog of human EGs is
to take advantage of essentiality in model organisms other than mouse. Large scale
phenotypic analysis of mutant strains has been performed in S. cerevisiae (Giaever et al.,
2002; Winzeler et al., 1999), C. elegans (Clark et al., 1988; Johnsen and Baillie, 1991),
D. melanogaster (Boutros et al., 2004; Dietzl et al., 2007; Kamath et al., 2003) and D.
rerio (zebrafish) (Amsterdam et al., 2004). Human orthologs of EGs in these organisms
are also plausible candidates for human EGs. However, since these organisms are not as
close evolutionary relatives to human as mouse, EGs in these organisms may not be
essential in mammals because of commonly occurring gene duplication during evolution
(Holland et al., 1994). Therefore, extra care should be taken when inferring human EGs
from these organisms. For example, human orthologs of EGs in multiple organisms could
be highly conserved during evolution and thus are more likely to be EGs in human.
Overall, a larger or eventually complete catalog of human EGs will further deepen our
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understanding of basic biological processes and their contribution of EGs to human
disease.
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